

Electronic Supplementary Information

Enantioselective rhodium/ruthenium photoredox catalysis en route to chiral 1,2-aminoalcohols

Jiajia Ma, Klaus Harms and Eric Meggers*

*Email: meggers@chemie.uni-marburg.de

| | |
|--|------------|
| 1. General Information..... | S2 |
| 2. Synthesis of Substrates..... | S3 |
| 2.1. Synthesis of 2-Acyl Imidazoles | S3 |
| 2.2. Synthesis of Aniline Derivatives | S13 |
| 3. Rhodium-Catalyzed Photoredox Reactions..... | S16 |
| 4. Chiral Chromatography | S37 |
| 5. Mechanistic Studies | S58 |
| 6. Single Crystal X-Ray Diffraction Studies | S61 |
| 7. References..... | S64 |
| 8. NMR Spectra | S65 |


1. General Information

All reactions were carried out under an atmosphere of nitrogen with magnetic stirring. Catalytic reactions were performed by using standard Schlenk glassware techniques. Solvents were distilled under nitrogen from calcium hydride (CH_3CN , CH_2Cl_2), sodium/benzophenone (THF, Et_2O). The N,N-dimethylacetamide (DMAC) was purchased from Aldrich and used without further purification. ^1H NMR and proton decoupled ^{13}C NMR spectra were recorded on Bruker Avance 300 (300 MHz), Bruker AM (500 MHz) spectrometers at ambient temperature. NMR standards were used as follows: ^1H NMR spectroscopy: $\delta = 7.26$ ppm (CDCl_3), $\delta = 5.32$ ppm (CD_2Cl_2), $\delta = 7.16$ ppm (C_6D_6). $^{13}\text{C}\{^1\text{H}\}$ NMR spectroscopy: $\delta = 77.1$ ppm (CDCl_3), $\delta = 53.8$ ppm (CD_2Cl_2), $\delta = 128.0$ ppm (C_6D_6). IR spectra were recorded on a Bruker Alpha FT-IR spectrophotometer or on a Nicolet Avatar 330 FT-IR spectrophotometer. CD spectra were recorded on a JASCO J-810 CD spectropolarimeter (600-200 nm, 1 nm band width, 50 nm/min scanning speed, accumulation of 3 scans). High-resolution mass spectra were recorded on a Bruker En Apex Ultra 7.0 TFT-MS instrument using ESI technique. Chiral HPLC chromatography was performed with an Agilent 1200, 1260 or Shimadzu Lc-2030c HPLC system. Optical rotations were measured with a Perkin-Elmer 241 or 341 polarimeter at concentrations of 1.0 g/100 mL. The anilines **2a**¹, **2d-g**¹, and **2h-i**² were prepared according to published procedures. All other reagents were commercially available and used without further purification.

2. Synthesis of Substrates


2.1. Synthesis of 2-Acyl Imidazoles

Method A



General procedure for the preparation of 1a-d with method A. To a mixture of **S1** (2.0 mmol) in CH₃CN (8 mL) was added **S2** (348 μ L, 3.0 mmol) dropwise at 0 °C, followed by the addition of Et₃N (420 μ L, 3.0 mmol), then stirred at room temperature for 12h. Afterwards, the reaction mixture was poured into H₂O (50 mL), extracted by EtOAc (3 \times 20 mL). The organic layer was collected and dried over anhydrous Na₂SO₄, filtered, then concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (EtOAc/*n*-hexane = 1:3).

(1-Methyl-1*H*-imidazol-2-yl)(phenyl)methanone (1a)



1-Methyl-1*H*-imidazole was converted to 2-acyl imidazole **1a** (316 mg, 1.70 mmol, 85% yield) as a pale yellow oil.


¹H NMR (300 MHz, CDCl₃) δ 8.23-8.21 (m, 2H), 7.50 (tt, *J* = 7.3, 2.3 Hz, 1H), 7.43-7.39 (m, 2H), 7.15 (d, *J* = 0.6 Hz, 1H), 7.01 (s, 1H), 3.96 (s, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 183.9, 142.9, 137.1, 132.4, 130.5, 129.0, 127.8, 126.6, 36.1.

IR (film): ν (cm⁻¹) 3107, 3063, 2956, 1706, 1639, 1597, 1507, 1448, 1393, 1292, 1257, 1165, 1077, 999, 935, 897, 770, 735, 681, 651, 618, 554.

HRMS (ESI, m/z) calcd for $C_{11}H_{11}N_2O^+$ $[M+H]^+$: 187.0866, found: 187.0866.

Phenyl(1-phenyl-1*H*-imidazol-2-yl)methanone (**1b**)



1-Phenyl-1*H*-imidazole was converted to 2-acyl imidazole **1b** (456 mg, 1.84 mmol, 92% yield) as a pale yellow oil.


1H NMR (300 MHz, $CDCl_3$) δ 8.28-8.25 (m, 2H), 7.59 (tt, $J = 7.3, 2.4$ Hz, 1H), 7.51-7.45 (m, 5H), 7.36 (d, $J = 0.9$ Hz, 1H), 7.35-7.32 (m, 2H), 7.28 (d, $J = 0.9$ Hz, 1H).

^{13}C NMR (75 MHz, $CDCl_3$) δ 182.9, 143.2, 138.5, 136.8, 133.0, 130.8, 129.6, 129.1, 128.5, 128.1, 126.3, 125.6.

IR (film): ν (cm^{-1}) 3061, 1647, 1594, 1494, 1445, 1395, 1337, 1302, 1240, 1162, 1100, 1073, 1001, 928, 893, 759, 687, 656, 576, 532.

HRMS (ESI, m/z) calcd for $C_{16}H_{13}N_2O^+$ $[M+H]^+$: 249.1022, found: 249.1023.

Phenyl(1-(*o*-tolyl)-1*H*-imidazol-2-yl)methanone (**1c**)



1-(*o*-Tolyl)-1*H*-imidazole was converted to 2-acyl imidazole **1c** (424 mg, 1.62 mmol, 81% yield) as a colorless oil.

1H NMR (300 MHz, $CDCl_3$) δ 8.32-8.28 (m, 2H), 7.57 (tt, $J = 7.4, 2.4$ Hz, 1H), 7.50-7.44 (m, 2H), 7.40 (d, $J = 1.0$ Hz, 1H), 7.39-7.27 (m, 3H), 7.22 (dd, $J = 7.6, 1.0$ Hz, 1H), 7.17 (d, $J = 1.0$ Hz, 1H).


^{13}C NMR (75 MHz, $CDCl_3$) δ 182.6, 143.7, 138.2, 136.7, 134.5, 132.9, 130.9, 130.8, 129.9, 129.0,

128.2, 126.6, 126.4, 126.1, 17.4.

IR (film): ν (cm⁻¹) 3062, 2922, 1646, 1592, 1494, 1447, 1395, 1334, 1300, 1243, 1203, 1161, 1087, 1038, 1002, 930, 894, 762, 688, 658, 551, 458.

HRMS (ESI, m/z) calcd for C₁₇H₁₅N₂O⁺ [M+H]⁺: 263.1179, found: 263.1180.

(1-([1,1'-Biphenyl]-2-yl)-1*H*-imidazol-2-yl)(phenyl)methanone (1d)




1-([1,1'-Biphenyl]-2-yl)-1*H*-imidazole was converted to 2-acyl imidazole **1d** (640 mg, 1.98 mmol, 99% yield) as a white solid.

¹H NMR (300 MHz, CDCl₃) δ 7.81-7.78 (m, 2H), 7.57-7.47 (m, 5H), 7.34 (t, J = 7.6 Hz, 2H), 7.24 (br, 1H), 7.19 (br, 1H), 7.15-7.08 (m, 3H), 7.00-6.96 (m, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 183.1, 144.1, 138.5, 137.8, 136.4, 136.3, 132.7, 130.9, 130.5, 129.5, 129.0, 128.4, 128.3, 128.2, 127.8, 127.5, 126.4, 126.2.

IR (film): ν (cm⁻¹) 3131, 3061, 1732, 1650, 1590, 1480, 1440, 1402, 1302, 1237, 1159, 1080, 1002, 930, 893, 763, 690, 653, 574, 523, 465.


HRMS (ESI, m/z) calcd for C₂₂H₁₆N₂NaO⁺ [M+Na]⁺: 347.1155, found: 347.1156.



General procedure for the preparation of 1e-g with method A. To a mixture of **S1d** (220 mg, 1.0

mmol) in CH₃CN (4 mL) was added **S3** (1.5 mmol) portionwise at 0 °C, followed by the addition of Et₃N (210 μL, 1.5 mmol), then stirred at room temperature for 12 h. Afterwards, the reaction mixture was poured into H₂O (25 mL), extracted by EtOAc (3 × 20 mL). The organic layer was collected and dried over anhydrous Na₂SO₄, filtered, then concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (EtOAc/*n*-hexane = 3:1).

(1-([1,1'-Biphenyl]-2-yl)-1*H*-imidazol-2-yl)(*p*-tolyl)methanone (1e)



4-Methylbenzoyl chloride was converted to 2-acyl imidazole **1e** (275 mg, 0.82 mmol, 82% yield) as a white solid.


¹H NMR (300 MHz, CDCl₃) δ 7.77-7.73 (m, 2H), 7.56-7.40 (m, 4H), 7.22 (d, *J* = 1.1 Hz, 1H), 7.18-7.08 (m, 6H), 7.02-7.00 (m, 2H), 2.38 (s, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 182.7, 144.2, 143.4, 138.3, 137.8, 136.4, 133.7, 130.7, 130.6, 129.2, 128.9, 128.4, 128.2 (2C), 128.1, 127.4, 126.4, 126.0, 21.6.

IR (film): ν (cm⁻¹) 3131, 3076, 3028, 1650, 1605, 1570, 1503, 1482, 1455, 1434, 1411, 1334, 1304, 1267, 1253, 1182, 1162, 1090, 994, 898, 832, 792, 778, 761, 735, 697, 658, 555, 482, 433.

HRMS (ESI, *m/z*) calcd for C₂₃H₁₈N₂NaO⁺ [M+Na]⁺: 361.1311, found: 361.1311.

(1-([1,1'-Biphenyl]-2-yl)-1*H*-imidazol-2-yl)(*m*-tolyl)methanone (1f)



3-Methylbenzoyl chloride was converted to 2-acyl imidazole **1f** (326 mg, 0.97 mmol, 97% yield) as a white solid.


^1H NMR (300 MHz, CDCl_3) δ 7.48 (d, $J = 7.6$ Hz, 1H), 7.43-7.36 (m, 3H), 7.35-7.30 (m, 2H), 7.19 (d, $J = 8.0$ Hz, 1H), 7.14-7.10 (m, 2H), 7.06 (d, $J = 1.1$ Hz, 1H), 7.04-6.96 (m, 3H), 6.89-6.85 (m, 2H), 2.23 (s, 3H).

^{13}C NMR (75 MHz, CDCl_3) δ 183.5, 144.3, 138.5, 137.9, 137.4, 136.4 (2C), 133.6, 131.0, 130.9, 129.4, 129.1, 128.4, 128.3 (2C), 127.8, 127.5, 126.5, 126.1, 21.3.

IR (film): ν (cm^{-1}) 3129, 3113, 1646, 1582, 1481, 1456, 1443, 1304, 1271, 1261, 1204, 1151, 1134, 1089, 1010, 942, 833, 778, 766, 736, 706, 698, 674, 584, 560, 536, 430.

HRMS (ESI, m/z) calcd for $\text{C}_{23}\text{H}_{19}\text{N}_2\text{O}^+$ $[\text{M}+\text{H}]^+$: 339.1492, found: 339.1491.

(1-([1,1'-Biphenyl]-2-yl)-1*H*-imidazol-2-yl)(4-chlorophenyl)methanone (1g)



4-Chlorobenzoyl chloride was converted to 2-acyl imidazole **1g** (304 mg, 0.85 mmol, 85% yield) as a pale yellow solid.


^1H NMR (300 MHz, CDCl_3) δ 7.76-7.72 (m, 2H), 7.57-7.50 (m, 2H), 7.48-7.42 (m, 2H), 7.31 (dt, $J = 8.8, 2.0$ Hz, 2H), 7.24 (d, $J = 1.1$ Hz, 1H), 7.22 (d, $J = 1.1$ Hz, 1H), 7.15-7.07 (m, 3H), 7.00-6.93 (m, 2H).

^{13}C NMR (75 MHz, CDCl_3) δ 181.6, 143.8, 139.2, 138.4, 137.8, 136.2, 134.6, 131.9, 130.9, 129.6, 129.1, 128.4, 128.3, 128.2, 128.1, 127.5, 126.4, 126.3.

IR (film): ν (cm^{-1}) 3094, 3059, 1656, 1584, 1504, 1482, 1448, 1434, 1409, 1393, 1235, 1168, 1143, 1083, 1007, 926, 899, 870, 827, 795, 734, 697, 683, 655, 592, 538, 499, 477.

HRMS (ESI, m/z) calcd for $\text{C}_{22}\text{H}_{15}\text{ClN}_2\text{NaO}^+$ $[\text{M}+\text{Na}]^+$: 381.0765, found: 381.0766.

Methyl 4-(1-([1,1'-biphenyl]-2-yl)-1H-imidazole-2-carbonyl)benzoate (**1h**)



Methyl 4-(chlorocarbonyl)benzoate was converted to 2-acyl imidazole **1h** (305 mg, 0.80 mmol, 80% yield) as a white solid.


^1H NMR (300 MHz, CDCl_3) δ 8.03 (d, $J = 8.5$ Hz, 2H), 7.83 (d, $J = 8.5$ Hz, 2H), 7.59-7.53 (m, 2H), 7.51-7.45 (m, 2H), 7.28 (d, $J = 2.4$ Hz, 2H), 7.19-7.08 (m, 3H), 6.99-6.95 (m, 2H), 3.95 (s, 3H).

^{13}C NMR (75 MHz, CDCl_3) δ 182.3, 166.4, 143.7, 139.8, 138.5, 137.8, 136.2, 133.3, 130.9, 130.3, 129.8, 129.2, 128.9, 128.5, 128.4, 128.2, 127.6, 126.6, 126.3, 52.3.

IR (film): ν (cm^{-1}) 3120, 3060, 2948, 1712, 1655, 1569, 1506, 1481, 1436, 1409, 1276, 1231, 1168, 1101, 1007, 924, 895, 865, 820, 776, 743, 700, 647, 613, 534, 495, 462.

HRMS (ESI, m/z) calcd for $\text{C}_{24}\text{H}_{18}\text{N}_2\text{NaO}_3^+$ [$\text{M}+\text{Na}$] $^+$: 405.1210, found: 405.1212.

(1-([1,1'-Biphenyl]-2-yl)-1H-imidazol-2-yl)(4-methoxyphenyl)methanone (**1i**)



4-Methoxybenzoyl chloride was converted to 2-acyl imidazole **1i** (258 mg, 0.73 mmol, 73% yield) as a pale yellow oil.

^1H NMR (300 MHz, CDCl_3) δ 7.88 (d, $J = 9.0$ Hz, 2H), 7.54-7.40 (m, 4H), 7.20 (d, $J = 0.8$ Hz, 1H), 7.14-7.06 (m, 4H), 7.00-6.97 (m, 2H), 6.84 (d, $J = 8.8$ Hz, 2H), 3.84 (s, 3H).


^{13}C NMR (75 MHz, CDCl_3) δ 181.7, 163.5, 144.4, 138.4, 137.9, 136.5, 133.0, 130.8, 129.2 (2C),

129.0, 128.4, 128.3 (2C), 127.5, 126.5, 125.9, 113.2, 55.4 .

IR (film): ν (cm⁻¹) 3061, 2906, 2935, 1643, 1595, 1507, 1481, 1444, 1399, 1306, 1249, 1154, 1026, 923, 898, 843, 763, 730, 695, 652, 619, 579, 562, 517.

HRMS (ESI, m/z) calcd for C₂₃H₁₈N₂NaO₂⁺ [M+Na]⁺: 377.1260, found: 377.1262.

4-(1-([1,1'-Biphenyl]-2-yl)-1H-imidazole-2-carbonyl)phenyl acetate (**1j**)



4-(Chlorocarbonyl)phenyl acetate was converted to 2-acyl imidazole **1j** (263 mg, 0.70 mmol, 70% yield) as a pale yellow solid.


¹H NMR (300 MHz, CDCl₃) δ 7.89 (d, J = 8.7 Hz, 2H), 7.55-7.40 (m, 4H), 7.20 (d, J = 10.7 Hz, 2H), 7.13-7.07 (m, 5H), 6.97-6.94 (m, 2H), 2.29 (s, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 181.6, 168.6, 154.2, 143.9, 138.4, 137.7, 136.3, 133.7, 132.2, 130.9, 129.4, 129.0, 128.4, 128.3, 128.2, 127.6, 126.4, 126.3, 120.9, 21.1..

IR (film): ν (cm⁻¹) 3120, 3060, 2948, 1712, 1655, 1506, 1481, 1436, 1276, 1231, 1168, 1101, 1007, 924, 896, 866, 821, 777, 744, 700, 647, 613, 534, 495, 462.

HRMS (ESI, m/z) calcd for C₂₄H₁₈N₂NaO₃⁺ [M+Na]⁺: 405.1210, found: 405.1212.

(1-([1,1'-Biphenyl]-2-yl)-1H-imidazol-2-yl)([1,1'-biphenyl]-4-yl)methanone (**1k**)



[1,1'-Biphenyl]-4-carbonyl chloride was converted to 2-acylimidazole **1k** (293 mg, 0.73 mmol, 73% yield) as a white solid.


¹H NMR (300 MHz, CDCl₃) δ 7.91 (dt, *J* = 8.5, 1.8 Hz, 2H), 7.66-7.58 (m, 4H), 7.56-7.45 (m, 6H), 7.41 (dt, *J* = 6.1, 1.4 Hz, 1H), 7.27 (d, *J* = 1.1 Hz, 1H), 7.21 (d, *J* = 1.1 Hz, 1H), 7.18-7.10 (m, 3H), 7.04-7.00 (m, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 182.6, 145.3, 144.2, 140.2, 138.4, 137.8, 136.4, 135.1, 131.0, 130.8, 129.4, 128.9, 128.8, 128.3 (2C), 128.2, 128.0, 127.5, 127.2, 126.5, 126.4, 126.2.

IR (film): ν (cm⁻¹) 1648, 1598, 1480, 1443, 1402, 1305, 1238, 1166, 1143, 1002, 929, 897, 847, 751, 727, 692, 655, 587, 558, 528, 490.

HRMS (ESI, *m/z*) calcd for C₂₈H₂₁N₂O⁺ [M+H]⁺: 401.1648, found: 401.1651.

Method B



Preparation of 1h with method B. To a solution of **S1d** (220 mg, 1.0 mmol) in THF (4 mL) was added $n\text{BuLi}$ (0.48 mL, 2.5 M in *n*-hexane, 1.2 mmol) at $-78\text{ }^\circ\text{C}$ dropwise. After stirred at this temperature for 1 h, **S4** (0.13 mL, 1.1 mmol) was added slowly. The reaction mixture was warmed to room temperature gradually, then stirred for another 15 h. Afterwards, the mixture was poured into saturated aqueous solution of NH_4Cl and extracted with EtOAc ($3 \times 20\text{ mL}$). The combined organic layers were dried over anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (EtOAc/*n*-hexane = 1:1) to give **1m** (197 mg, 0.75 mmol, 75% yield) as a white solid.

1-(1-([1,1'-Biphenyl]-2-yl)-1H-imidazol-2-yl)ethanone (**1m**)


^1H NMR (300 MHz, CDCl_3) δ 7.54-7.32 (m, 3H), 7.32-7.29 (m, 1H), 7.23-7.20 (m, 3H), 7.13 (d, $J = 0.9\text{ Hz}$, 1H), 7.05 (d, $J = 0.9\text{ Hz}$, 1H), 7.00-6.94 (m, 2H), 2.31 (s, 3H).

^{13}C NMR (75 MHz, CDCl_3) δ 188.8, 143.9, 138.6, 137.8, 136.2, 130.7, 129.3, 129.0, 128.1 (2C), 127.4, 126.8, 126.4, 26.6.

IR (film): ν (cm^{-1}) 3032, 2921, 2851, 1682, 1504, 1483, 1447, 1434, 1403, 1357, 1337, 1304, 1267, 1224, 1158, 1145, 1128, 1101, 1085, 1017, 763, 714, 702, 680, 610, 563, 430.

HRMS (ESI, m/z) calcd for $\text{C}_{17}\text{H}_{15}\text{N}_2\text{O}^+$ $[\text{M}+\text{H}]^+$: 263.1179, found: 263.1180.

Method C



Preparation of 11 with method C. To a solution of **S1d** (220 mg, 1.0 mmol) in THF (4 mL) was added *n*BuLi (0.48 mL, 2.5 M in *n*-hexane, 1.2 mmol) at -78 °C dropwise. After stirred at this temperature for 1 h, **S5** (0.16 mL, 1.2 mmol) was added slowly. The reaction mixture was warmed to room temperature gradually, then stirred for another 15 h. Afterwards, the mixture was poured into saturated aqueous solution of Na₂CO₃ and extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (EtOAc/*n*-hexane = 1:1) to give **11** (180 mg, 0.66 mmol, 66% yield) as a colorless oil.

1-(1-([1,1'-Biphenyl]-2-yl)-1H-imidazol-2-yl)propan-1-one (**11**)

¹H NMR (300 MHz, CDCl₃) δ 7.54-7.42 (m, 3H), 7.34-7.30 (m, 1H), 7.23-7.18 (m, 3H), 7.13 (d, *J* = 1.0 Hz, 1H), 7.07 (d, *J* = 1.1 Hz, 1H), 6.98-6.94 (m, 2H), 2.99-2.85 (m, 1H), 2.63-2.50 (m, 1H), 0.93 (t, *J* = 7.3 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 192.1, 143.7, 138.7, 138.0, 136.4, 130.7, 129.2, 129.0, 128.2 (2C), 127.4, 126.5, 126.4, 32.0, 7.7.


IR (film): ν (cm⁻¹) 2975, 2936, 1683, 1505, 1482, 1455, 1446, 1378, 1324, 1303, 1210, 1145, 1075, 1021, 1009, 938, 909, 803, 763, 735, 699, 645, 611, 573, 554, 505.

HRMS (ESI, *m/z*) calcd for C₁₈H₁₇N₂O⁺ [M+H]⁺: 277.1335, found: 277.1335.

2.2. Synthesis of Aniline Derivatives

The anilines **2a**¹, **2d-g**¹, and **2h-i**² were prepared according to the published procedure.

Preparation of **2b**:



Procedure for the preparation of (chloromethyl)dicyclopropyl(methyl)silane (S6). To a stirred suspension of granular lithium (278 mg, 40 mmol) in diethyl ether (10 mL) at 0 °C was added a solution of bromocyclopropane (1.60 mL, 20 mmol) in diethyl ether (10 mL) dropwise within 10 min, and the resulting mixture was stirred at 0 °C for another 60 min. Afterwards, a solution of dichloro(chloromethyl)methylsilane (1.31 mL, 10 mmol) in diethyl ether (5 mL) was added dropwise with 10 min at 0 °C. Subsequently, the reaction mixture was stirred at this temperature for another 45 min, then poured into water (30 mL). The organic phase was separated and the aqueous layer was extracted with diethyl ether (3 × 20 mL). The combined organic extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to furnish **S6** (1.40 g, 8.0 mmol, 80% yield, > 95% purity judged by ¹H NMR) as a pale yellow oil.

¹H NMR (300 MHz, CDCl₃) δ 2.83 (s, 2H), 0.63-0.57 (m, 4H), 0.35-0.30 (m, 4H), -0.11 (s, 3H), -0.39 (tt, *J* = 9.8, 6.9 Hz, 2H).

All spectroscopic data was in agreement with the literature.³

Procedure for the preparation of dicyclopropyl(iodomethyl)(methyl)silane (S7). A suspension of **S6** (1.40 g, 8.0 mmol) and NaI (6.01 g, 40 mmol) in acetone (15 mL) was heated at 65 °C for 6h. Afterwards, the reaction mixture was poured into water (100 mL), extracted with diethyl ether (3 × 30 mL). The combined organic extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to furnish **S7** (1.75 g, 6.56 mmol, 82% yield, >95% purity judged by ¹H-NMR) as a pale yellow oil.

^1H NMR (300 MHz, CDCl_3) δ 2.03 (s, 2H), 0.65-0.58 (m, 4H), 0.34-0.28 (m, 4H), -0.10 (s, 3H), -0.38 (tt, $J = 9.8, 6.9$ Hz, 2H).

^{13}C NMR (75 MHz, CDCl_3) δ 1.3, 1.1, -7.3 , -7.7 , -15.2 .

IR (film): ν (cm^{-1}) 3070, 2997, 1287, 1252, 1186, 1099, 1078, 1053, 1032, 896, 822, 790, 773, 784, 722, 690, 661, 516.

Procedure for the preparation of *N*-((dicyclopropyl(methyl)silyl)methyl)-*N*-methylaniline (2b).


To a stirred solution of *N*-methylaniline (0.43 mL, 4.0 mmol) in THF (10 mL) at 0 °C was added *n*BuLi (2.4 mL, 2.5 M in *n*-hexane, 6.0 mmol) dropwise. After stirred at 0 °C for 2 h, **S7** (1.28 g, 4.80 mmol) was added to the mixture slowly, and the resulting solution was stirred for another 15 h. The reaction was then quenched by slow addition of a saturated solution of NH_4Cl (15 mL) and extracted with EtOAc (3×20 mL). The combined organic extracts were dried over anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was subjected to a flash chromatography on silica gel (EtOAc/*n*-hexane = 1:30) to give **2b** (785 mg, 3.20 mmol, 80% yield) as a pale yellow oil.

^1H NMR (300 MHz, CDCl_3) δ 7.47-7.40 (m, 2H), 6.96-6.93 (m, 2H), 6.85 (tt, $J = 7.3, 0.8$ Hz, 1H), 3.22 (s, 3H), 3.17 (s, 2H), 0.83-0.77 (m, 4H), 0.53-0.50 (m, 4H), 0.00 (s, 3H), -0.23 (tt, $J = 9.8, 6.9$ Hz, 2H).

^{13}C NMR (75 MHz, CDCl_3) δ 150.7, 128.8, 115.0, 111.9, 42.2, 40.2, 1.4, 1.0, -7.1 , -8.5 .

IR (film): ν (cm^{-1}) 3068, 2996, 2925, 2802, 1597, 1504, 1365, 1286, 1251, 1233, 1192, 1097, 1032, 989, 897, 821, 799, 772, 743, 689, 631, 512, 400.

HRMS (ESI, m/z) calcd for $\text{C}_{15}\text{H}_{24}\text{NSi}^+$ $[\text{M}+\text{H}]^+$: 246.1673, found: 246.1673.



Procedure for the preparation of 3-chloro-*N*-methyl-*N*-((trimethylsilyl)methyl)aniline (2j). To a stirred solution of 3-Chloro-*N*-methylaniline (0.61 mL, 5.0 mmol) in THF (12 mL) at 0 °C was

added *n*BuLi (2.4 mL, 2.5 M in *n*-hexane, 6.0 mmol) dropwise. After stirred at 0 °C for 2 h, (Iodomethyl)trimethylsilane (1.11 mL, 7.50 mmol) was added to the mixture slowly, and the resulting solution was stirred for another 15 h. The reaction was then quenched by slow addition of a saturated solution of NH₄Cl (15 mL) and extracted with EtOAc (3 × 20 mL). The combined organic extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was subjected to a flash chromatography on silica gel (EtOAc/*n*-hexane = 1:30) to give **2j** (830 mg, 3.64 mmol, 73% yield) as a pale yellow oil.

¹H NMR (300 MHz, CDCl₃) δ 7.10 (t, *J* = 8.0 Hz, 2H), 6.60-6.48 (m, 3H), 2.94 (s, 3H), 2.87 (s, 2H), 0.11 (s, 9H).


¹³C NMR (75 MHz, CDCl₃) δ 151.2, 134.9, 129.8, 114.8, 111.4, 109.8, 43.9, 40.1, -1.2.

IR (film): ν (cm⁻¹) 2953, 2894, 2809, 1591, 1557, 1493, 1366, 1247, 1232, 1195, 1099, 986, 837, 753, 680, 661, 443.

HRMS (ESI, *m/z*) calcd for C₁₁H₁₉ClNSi⁺ [M+H]⁺: 228.0970, found: 228.0970.

3. Rhodium-Catalyzed Photoredox Reactions

General procedure for entries 1-6 of Table 1. A dried 10 mL Schlenk tube was charged with the catalyst Λ -**RhO** (4 mol%) (entries 1-5) or Λ -**IrO** (4 mol%) (entry 6), the photosensitizer [Ru(bpy)₃](PF₆)₂ (0.86 mg, 0.001 mmol, 1 mol%) and the corresponding 2-acyl imidazoles (0.10 mmol, 1.0 eq.). A solution of **2a** (29.0 mg, 0.15 mmol, 1.5 eq.) in MeCN/DMAC (v/v = 4:1, 1 mL) was added in one portion. The reaction mixture was degassed *via* freeze-pump-thaw for three cycles. After the mixture was thoroughly degassed, the vial was sealed and positioned approximately 5 cm from a 23 W compact fluorescent lamp. The reaction was stirred at room temperature for the indicated time (monitored by TLC) under nitrogen atmosphere. Afterwards, the mixture was concentrated under reduced pressure. The residue was redissolved in THF (2 mL), and then TBAF (0.5 mL, 1.0 M in THF, 0.5 mmol) was added (except entry 1). The mixture was stirred at room temperature for another 0.5 h and quenched by the addition of saturated aqueous solution of NH₄Cl, extracted by EtOAc (3 × 10 mL). The combined organic layers were concentrated and subjected to a flash chromatography on silica gel (EtOAc/*n*-hexane = 1:7 to 1:4) to afford the products **3a'-d**. Racemic samples were obtained by carrying out the reactions with *rac*-**RhO**. The enantiomeric excess was determined by chiral HPLC analysis.




As for entry 1, starting from **1a** (18.6 mg, 0.10 mmol) and **2a** (29.0 mg, 0.15 mmol) according to the general procedure without treating with TBAF to give **3a'** as a pale yellow oil (27.0 mg, 0.68 mmol, 68% yield). Enantiomeric excess established by HPLC analysis by using a Chiralpak OD-H column, ee = 41% (HPLC: OD-H, 254 nm, *n*-hexane/isopropanol = 95: 5, flow rate 0.5 mL/min, 25 °C, t_r (minor) = 9.6 min, t_r (major) = 11.2 min); $[\alpha]_D^{20} = +38.0^\circ$ (*c* 1.0, CH₂Cl₂)

¹H NMR (300 MHz, CD₂Cl₂) δ 7.28-7.23 (m, 2H), 7.19-7.07 (m, 3H), 7.00 (d, $J = 1.2$ Hz, 1H), 6.97-6.90 (m, 2H), 6.82 (d, $J = 1.1$ Hz, 1H), 6.50-6.44 (m, 3H), 4.76 (d, $J = 15.1$ Hz, 1H), 4.02 (d, $J = 15.1$ Hz, 1H), 2.97 (s, 6H), 0.02 (s, 9H).

^{13}C NMR (75 MHz, CD_2Cl_2) δ 151.0, 149.5, 144.0, 128.5, 127.9, 127.2, 126.7, 126.4, 123.3, 116.1, 112.8, 79.7, 62.6, 39.4, 34.7.

IR (film): ν (cm^{-1}) 3060, 3025, 2953, 2897, 1598, 1505, 1448, 1403, 1368, 1343, 1279, 1262, 1251, 1195, 1125, 1088, 1064, 1016, 992, 959, 883, 840, 744, 725, 690, 582, 462.

HRMS (ESI, m/z) calcd for $\text{C}_{22}\text{H}_{30}\text{N}_3\text{OSi}^+$ $[\text{M}+\text{H}]^+$: 380.2153, found: 380.2158.



As for entry 2, starting from **1a** (18.6 mg, 0.10 mmol) and **2a** (29.0 mg, 0.15


mmol) according to the general procedure to give **3a** as a pale yellow oil (22.4 mg, 0.729 mmol, 73% yield). Enantiomeric excess established by HPLC analysis by using a Chiralpak OD-H column, ee = 41% (HPLC: OD-H, 254 nm, *n*-hexane/isopropanol = 95: 5, flow rate 0.5 mL/min, 25 °C, t_r (minor) = 20.4 min, t_r (major) = 15.2 min); $[\alpha]_D^{20} = +50.4^\circ$ (*c* 1.0, CH_2Cl_2)

^1H NMR (300 MHz, CDCl_3) δ 7.40-7.32 (m, 4H), 7.30-7.19 (m, 3H), 7.01 (d, $J = 1.2$ Hz, 1H), 6.94-6.90 (m, 2H), 6.83-6.78 (m, 2H), 4.82 (d, $J = 14.9$ Hz, 1H), 3.96 (br, 1H), 3.74 (d, $J = 14.9$ Hz, 1H), 3.41 (s, 3H), 2.76 (s, 3H).

^{13}C NMR (75 MHz, CDCl_3) δ 152.0, 149.4, 144.3, 129.2, 128.7, 127.5, 126.0, 125.2, 123.1, 118.8, 114.5, 74.7, 65.1, 39.8, 34.4.

IR (film): ν (cm^{-1}) 3059, 2952, 2870, 2758, 1597, 1503, 1448, 1407, 1346, 1279, 1256, 1174, 1145, 1123, 1092, 1064, 1031, 991, 966, 938, 900, 745, 730, 696, 645, 589, 562, 470.

HRMS (ESI, m/z) calcd for $\text{C}_{19}\text{H}_{22}\text{N}_3\text{O}^+$ $[\text{M}+\text{H}]^+$: 308.1757, found: 308.1753.



As for entry 3, starting from **1b** (24.8 mg, 0.10 mmol) and **2a** (29.0 mg, 0.15

mmol) according to the general procedure to give **3b** as a white solid (27.0 mg, 0.740 mmol, 74%


yield). Enantiomeric excess established by HPLC analysis by using a Chiralpak AD-H column, ee = 82% (HPLC: AD-H, 254 nm, *n*-hexane/isopropanol = 90: 10, flow rate 1.0 mL/min, 25 °C, t_r (minor) = 14.0 min, t_r (major) = 9.9 min); $[\alpha]_D^{20} = +56.6^\circ$ (*c* 1.0, CH₂Cl₂)

¹H NMR (300 MHz, CD₂Cl₂) δ 7.26-7.18 (m, 6H), 7.17-7.12 (m, 4H), 7.11 (d, *J* = 1.2 Hz, 1H), 6.97 (d, *J* = 1.3 Hz, 1H), 6.89-6.83 (m, 4H), 6.73 (tt, *J* = 7.3, 0.8 Hz, 1H) 4.78 (d, *J* = 14.9 Hz, 1H), 3.75 (d, *J* = 14.9 Hz, 1H), 3.54 (br, 1H), 2.70 (s, 3H).

¹³C NMR (75 MHz, CD₂Cl₂) δ 152.3, 150.4, 145.2, 139.2, 129.2, 128.5, 128.4, 128.2, 127.7, 127.3, 126.7, 125.6, 124.4, 118.4, 114.4, 75.6, 65.5, 39.7.

IR (film): ν (cm⁻¹) 3059, 3025, 2870, 2729, 1597, 1496, 1446, 1352, 1302, 1253, 1175, 1138, 1122, 1096, 1065, 1031, 990, 937, 897, 746, 727, 689, 595, 538, 514.

HRMS (ESI, *m/z*) calcd for C₂₄H₂₃N₃NaO⁺ [M+Na]⁺: 392.1733, found: 392.1732.




As for entry 4, starting from **1c** (26.2 mg, 0.10 mmol) and **2a** (29.0 mg, 0.15 mmol) according to the general procedure to give **3c** as a white solid (28.0 mg, 0.73 mmol, 73% yield). Enantiomeric excess established by HPLC analysis by using a Chiralpak OD-H column, ee = 88% (HPLC: OD-H, 254 nm, *n*-hexane/isopropanol = 95: 5, flow rate 0.5 mL/min, 25 °C, t_r (minor) = 12.3 min, t_r (major) = 13.7 min); $[\alpha]_D^{20} = +70.2^\circ$ (*c* 1.0, CH₂Cl₂).

¹H NMR (300 MHz, CDCl₃, mixture of rotamers) δ 7.32-7.28 (m, 1H), 7.57 (tt, *J* = 7.3, 1.3 Hz, 0.8 H), 7.47 (tt, *J* = 7.7, 1.4 Hz, 0.2 H, other rotamer), 7.42-7.30 (m, 1H), 7.36-7.25 (m, 1H), 7.24-7.21 (m, 2H), 7.20-7.18 (m, 3H), 7.17-7.15 (m, 2H), 7.15-7.12 (m, 1H), 6.92-6.83 (m, 2H), 6.82-6.74 (m, 2H), 6.12 (d, *J* = 7.8 Hz, 0.8 H, other rotamer), 4.92 (d, *J* = 14.7 Hz, 0.8 H), 4.78 (d, *J* = 14.7 Hz, 0.2 H, other rotamer), 3.83 (d, *J* = 2.7 Hz, 0.8 H), 3.78 (d, *J* = 2.8 Hz, 0.2 H, other rotamer), 2.56 (br, 0.8 H), 2.51 (br, 0.2 H, other rotamer), 2.72 (s, 2.4 H), 2.64 (s, 0.6 H, other rotamer), 2.08 (s, 2.4 H), 2.06 (s, 0.6 H, other rotamer).

^{13}C NMR (125 MHz, CD_2Cl_2 , mixture of rotamers) δ 152.4 (2C), 150.3, 150.2, 145.4, 144.3, 138.5, 138.0, 136.5, 135.8, 130.5, 130.3, 129.9, 129.2, 128.8 (2C), 128.5, 128.2, 128.1, 127.5, 127.1, 126.9, 126.7, 125.9, 125.7, 123.8, 123.6, 118.7, 118.5, 114.6, 115.5, 75.5, 75.2, 66.0, 65.4, 39.6, 17.6, 17.0.

IR (film): ν (cm^{-1}) 3058, 3025, 2924, 2855, 1598, 1495, 1446, 1351, 1301, 1253, 1175, 1139, 1120, 1093, 1064, 1032, 991, 938, 848, 747, 721, 693, 674, 645, 602, 547, 516, 456.

HRMS (ESI, m/z) calcd for $\text{C}_{25}\text{H}_{26}\text{N}_3\text{O}^+$ $[\text{M}+\text{H}]^+$: 384.2070, found: 384.2071.



As for entry 5, starting from **1d** (32.4 mg, 0.10 mmol) and **2a** (29.0 mg, 0.15 mmol) according to the general procedure to give **3d** as a white solid (32.0 mg, 0.072 mmol, 72% yield). Enantiomeric excess established by HPLC analysis by using a Chiralpak OD-H column, ee = 93% (HPLC: OD-H, 254 nm, *n*-hexane/isopropanol = 95: 5, flow rate 0.5 mL/min, 25 °C, t_r (minor) = 15.8 min, t_r (major) = 13.3 min).

^1H NMR (300 MHz, CDCl_3) δ 7.46-7.26 (m, 9H), 7.24-7.16 (m, 3H), 7.12-6.98 (m, 3H), 6.87-6.74 (m, 4H), 6.67 (d, J = 1.1 Hz, 1H), 6.39 (d, J = 7.8 Hz, 1H), 4.70 (d, J = 14.8 Hz, 1H), 3.72 (d, J = 14.8 Hz, 1H), 3.50 (br, 1H), 2.66 (s, 3H).


^{13}C NMR (75 MHz, CDCl_3) δ 151.6, 149.8, 145.0, 138.8, 138.7, 137.1, 130.3, 128.9, 128.6, 128.3 (2C), 128.2, 128.1, 127.3, 127.2, 127.1, 126.3, 125.0, 124.2, 118.4, 114.2, 75.4, 65.2, 39.1.

IR (film): ν (cm^{-1}) 3060, 3020, 1596, 1572, 1502, 1485, 1447, 1436, 1356, 1341, 1327, 1255, 1182, 1097, 1068, 1031, 1008, 992, 958, 940, 909, 767, 751, 732, 699, 672, 547, 463.

HRMS (ESI, m/z) calcd for $\text{C}_{30}\text{H}_{27}\text{N}_3\text{NaO}^+$ $[\text{M}+\text{Na}]^+$: 468.2046, found: 468.2047.

General procedure for entries 7 and 10 of Table 1. A dried 10 mL Schlenk tube was charged with the catalyst Λ -IrO (3.70 mg, 0.004 mmol, 4 mol%) (entry 7) or Λ -RhS (3.50 mg, 0.004 mmol, 4 mol%) (entry 10) and the 2-acyl imidazole **1d** (32.4 mg, 0.10 mmol, 1.0 eq.). A solution of **2a** (29.0


mg, 0.15 mmol, 1.5 eq.) in MeCN/DMAC (v/v = 4:1, 1 mL) was added in one portion. The reaction mixture was degassed *via* freeze-pump-thaw for three cycles. After the mixture was thoroughly degassed, the vial was sealed and positioned approximately 5 cm from a 23 W compact fluorescent lamp. The reaction was stirred at room temperature for 24 h or 20 h under nitrogen atmosphere. Afterwards, the mixture was concentrated under reduced pressure. The residue was redissolved in THF (2 mL), then TBAF (0.5 mL, 1.0 M in THF, 0.5 mmol) was added. The mixture was stirred at room temperature for another 0.5 h and quenched by the addition of saturated aqueous solution of NH₄Cl, extracted by EtOAc (3 × 10 mL). The combined organic layers were concentrated. The conversion was determined by the crude ¹H NMR analysis.



As for entry 7, starting from **1d** (32.4 mg, 0.10 mmol) and **2a** (29.0 mg, 0.15 mmol) according to the general procedure to give **3d** as a white solid (19.0 mg, 0.430 mmol, 43% yield). Enantiomeric excess established by HPLC analysis by using a Chiralpak OD-H column, ee = 3% (HPLC: OD-H, 254 nm, *n*-hexane/isopropanol = 95: 5, flow rate 0.5 mL/min, 25 °C, *t_r* (minor) = 15.1 min, *t_r* (major) = 13.3 min).


General procedure for entries 8-9 and 11-12 of Table 1. A dried 10 mL Schlenk tube was charged with the catalyst Λ -**RhS** (3.50 mg, 0.004 mmol, 4 mol%), the photosensitizer [Ru(bpy)₃](PF₆)₂ (0.86 mg, 0.001 mmol, 1 mol%) and 2-acyl imidazole **1d** (32.4 mg, 0.10 mmol, 1.0 eq.). A solution of **2a-c** (0.15 mmol, 1.5 eq.) in MeCN/DMAC (v/v = 4:1, 1 mL) was added in one portion. The reaction mixture was degassed *via* freeze-pump-thaw for three cycles. After the mixture was thoroughly degassed, the vial was sealed and positioned approximately 5 cm from a 23 W compact fluorescent lamp (the catalytic reaction of entry 8 was conducted in the dark). The reaction was stirred at room temperature for the indicated time (monitored by TLC) under nitrogen atmosphere. Afterwards, the mixture was concentrated under reduced pressure. The residue was redissolved in THF (2 mL), then TBAF (0.5 mL, 1.0 M in THF, 0.5 mmol) was added. The mixture was stirred at room temperature for another 0.5 h and quenched by the addition of saturated aqueous solution of NH₄Cl, extracted by EtOAc (3 × 10 mL). The combined organic layers were concentrated. The

conversion was determined by the crude ^1H NMR analysis. If the product was detected in the crude ^1H NMR, the residue was subjected to a flash chromatography on silica gel (EtOAc/*n*-hexane = 1:7 to 1:4) to afford the products **3d**. The enantiomeric excess was determined by chiral HPLC analysis.




As for entry 8, starting from **1d** (32.4 mg, 0.10 mmol) and **2a** (29.0 mg, 0.15 mmol) according to the general procedure to give **3d** as a white solid (33.8 mg, 0.760 mmol, 76% yield). Enantiomeric excess established by HPLC analysis by using a Chiralpak OD-H column, ee = 95% (HPLC: OD-H, 254 nm, *n*-hexane/isopropanol = 95: 5, flow rate 0.5 mL/min, 25 °C, t_r (minor) = 15.1 min, t_r (major) = 13.3 min); $[\alpha]_D^{20} = -6.6^\circ$ (*c* 1.0, CH_2Cl_2).


All other spectroscopic data was in agreement with former.



As for entry 11, starting from **1d** (32.4 mg, 0.10 mmol) and **2b** (36.8 mg, 0.15 mmol) according to the general procedure to give **3d** as a white solid (3.0 mg, 0.070 mmol, 7% yield). Enantiomeric excess established by HPLC analysis by using a Chiralpak OD-H column, ee = 79% (HPLC: OD-H, 254 nm, *n*-hexane/isopropanol = 95: 5, flow rate 0.5 mL/min, 25 °C, t_r (minor) = 15.1 min, t_r (major) = 13.3 min).

General procedure for Figure 2. A dried 10 mL Schlenk tube was charged with the catalyst Δ -RhS (5.2 mg, 0.0060 mmol, 4 mol%), the photosensitizer [Ru(bpy)₃](PF₆)₂ (1.30 mg, 0.0015 mmol, 1 mol%) and 2-acyl imidazole **1d** (48.6 mg, 0.150 mmol, 1.0 eq.). A solution of **2d** (0.45 mmol, 3.0 eq.) or **2e-i** (0.225 mmol, 1.5 eq.) in MeCN/DMAC (v/v = 4:1, 1.5 mL) was added in one portion. The reaction mixture was degassed *via* freeze-pump-thaw for three cycles. After the mixture was thoroughly degassed, the vial was sealed and positioned approximately 5 cm from a 23 W compact fluorescent lamp. The reaction was stirred at room temperature for the indicated time (monitored by TLC) under nitrogen atmosphere. Afterwards, the mixture was concentrated under reduced pressure. The residue was redissolved in THF (2 mL), then TBAF (1.0 mL, 1.0 M in THF, 1.0 mmol) was added. The mixture was stirred at room temperature for another 0.5 h and quenched by the addition of saturated aqueous solution of NH₄Cl, extracted by EtOAc (3 × 10 mL). The combined organic layers were concentrated. The residue was subjected to a flash chromatography on silica gel (EtOAc/*n*-hexane = 1:7 to 1:4) to afford the products **3e-j**. The enantiomeric excess was determined by chiral HPLC analysis.






Starting from **1d** (48.9 mg, 0.15 mmol) and **2d** (93.2 mg, 0.45 mmol) with Λ -**RhS** for 5 h according to the general procedure to give **3e** as a pale yellow oil (55.0 mg, 0.120 mmol, 80% yield). Enantiomeric excess established by HPLC analysis by using a Chiralpak AD-H column, ee = 98% (HPLC: AD-H, 254 nm, *n*-hexane/isopropanol = 90: 10, flow rate 1.0 mL/min, 25 °C, t_r (minor) = 9.9 min, t_r (major) = 6.0 min); $[\alpha]_D^{20} = -24.0^\circ$ (*c* 1.0, CH₂Cl₂).

¹H NMR (500 MHz, CD₂Cl₂) δ 7.42-7.32 (m, 6H), 7.30-7.22 (m, 6H), 7.07 (td, *J* = 8.3, 2.3 Hz, 1H), 6.98 (d, *J* = 8.5 Hz, 2H), 6.91 (d, *J* = 0.8 Hz, 1H), 6.73 (d, *J* = 8.7 Hz, 2H), 6.63 (d, *J* = 1.0 Hz, 1H), 6.35 (d, *J* = 7.9 Hz, 1H), 4.63 (d, *J* = 14.7 Hz, 1H), 3.73 (br, 1H), 3.58 (d, *J* = 14.7 Hz, 1H), 2.62 (s, 3H), 2.22 (s, 3H).

¹³C NMR (125 MHz, CD₂Cl₂) δ 150.2, 145.8, 139.2, 139.0, 137.5, 130.6, 129.7, 128.8, 128.7, 128.6, 128.5 (2C), 128.2, 128.1, 127.6, 127.5, 126.4, 125.8, 125.4, 124.5, 114.9, 75.5, 66.4, 39.4, 20.3.

IR (film): ν (cm⁻¹) 3059, 3028, 2924, 2860, 1615, 1599, 1517, 1483, 1446, 1352, 1303, 1252, 1177, 1139, 1117, 1097, 1068, 806, 765, 739, 699, 526, 514, 450, 410, 391.

HRMS (ESI, *m/z*) calcd for C₃₁H₃₀N₃O⁺ [M+H]⁺: 460.2383, found: 460.2385.



Starting from **1d** (48.9 mg, 0.15 mmol) and **2g** (46.6 mg, 0.225 mmol) with Λ -**RhS** for 10 h according to the general procedure to give **3f** as a pale yellow oil (56.0 mg, 0.122 mmol, 81% yield). Enantiomeric excess established by HPLC analysis by using a Chiralpak AD-H column, ee = 97% (HPLC: AD-H, 254 nm, *n*-hexane/isopropanol = 90: 10, flow rate 1.0 mL/min, 25 °C, t_r (minor) = 6.8 min, t_r (major) = 6.0 min); $[\alpha]_D^{20} = -30.4^\circ$ (*c* 1.0, CH₂Cl₂).


¹H NMR (500 MHz, CD₂Cl₂) δ 7.41-7.33 (m, 6H), 7.31-7.23 (m, 6H), 7.08-7.06 (m, 1H), 7.04 (d, *J*

= 7.8 Hz, 1H), 6.92 (d, $J = 1.0$ Hz, 1H), 6.64-6.60 (m, 3H), 6.58 (d, $J = 7.4$ Hz, 1H), 6.33 (d, $J = 7.7$ Hz, 1H), 4.65 (d, $J = 14.7$ Hz, 1H), 3.66 (d, $J = 14.7$ Hz, 1H), 3.56 (s, 1H), 2.64 (s, 3H), 2.25 (s, 3H).

^{13}C NMR (125 MHz, CD_2Cl_2) δ 152.2, 150.1, 145.7, 139.1, 139.0, 138.9, 137.5, 130.6, 129.0, 128.8, 128.7, 128.6, 128.5, 127.6, 127.5 (2C), 126.4, 125.4, 124.5, 119.6, 115.3, 111.7, 75.8, 65.8, 39.4, 21.9.

IR (film): ν (cm^{-1}) 3058, 2922, 2859, 2811, 1601, 1581, 1494, 1482, 1352, 1303, 1257, 1172, 1139, 1095, 1067, 1030, 1009, 995, 961, 945, 841, 764, 737, 698, 675, 610, 559, 446.

HRMS (ESI, m/z) calcd for $\text{C}_{31}\text{H}_{30}\text{N}_3\text{O}^+$ [$\text{M}+\text{H}$] $^+$: 460.2383, found: 460.2386.




Starting from **1d** (48.9 mg, 0.15 mmol) and **2f** (60.6 mg, 0.225 mmol) with Λ -**RhS** for 10 h according to the general procedure to give **3g** as a pale white solid (61.0 mg, 0.117 mmol, 78% yield). Enantiomeric excess established by HPLC analysis by using a Chiralpak OD-H column, ee = 93% (HPLC: OD-H, 254 nm, *n*-hexane/isopropanol = 90: 10, flow rate 0.5 mL/min, 25 °C, t_r (minor) = 11.2 min, t_r (major) = 10.0 min); $[\alpha]_{\text{D}}^{20} = -5.2^\circ$ (c 1.0, CH_2Cl_2).

^1H NMR (500 MHz, CD_2Cl_2) δ 7.44 (dd, $J = 7.6, 1.6$ Hz, 1H), 7.42 (dd, $J = 7.3, 0.8$ Hz, 1H), 7.38-7.36 (m, 2H), 7.32-7.28 (m, 6H), 7.24-7.21 (m, 5H), 7.19-7.18 (m, 1H), 7.12 (t, $J = 7.3$ Hz, 2H), 7.07 (td, $J = 7.9, 1.7$ Hz, 1H), 7.01 (d, $J = 7.2$ Hz, 2H), 6.97 (s, 1H), 6.79 (d, $J = 8.2$ Hz, 2H), 6.67 (d, $J = 1.0$ Hz, 1H), 6.35 (d, $J = 7.7$ Hz, 1H), 4.89 (d, $J = 15.0$ Hz, 1H), 4.47 (d, $J = 17.3$ Hz, 1H), 4.09 (d, $J = 17.3$ Hz, 1H), 4.04 (d, $J = 15.0$ Hz, 1H), 3.31 (br, 1H).

^{13}C NMR (125 MHz, CDCl_3) δ 149.7 (2C), 144.9, 138.9, 138.6, 137.7, 136.8, 130.4, 128.9, 128.7, 128.4, 128.3 (2C), 128.1, 127.4, 127.3, 127.2, 126.7, 126.4, 126.3, 125.3, 125.1, 124.2, 118.1, 114.5, 76.1, 62.3, 53.5.

IR (film): ν (cm⁻¹) 3060, 3027, 2930, 1964, 1598, 1503, 1483, 1450, 1384, 1450, 1384, 1360, 1303, 1265, 1231, 1197, 1138, 1070, 990, 767, 748, 728, 697, 675, 608, 557, 535, 512, 458.

HRMS (ESI, m/z) calcd for C₃₆H₃₂N₃O⁺ [M+H]⁺: 522.2540, found: 522.2545.




Starting from **1d** (48.9 mg, 0.15 mmol) and **2g** (49.4 mg, 0.225 mmol) with Λ -**RhS** for 15 h according to the general procedure to give **3h** as a pale yellow oil (49.0 mg, 0.105 mmol, 70% yield). Enantiomeric excess established by HPLC analysis by using a Chiralpak OD-H column, ee = 95% (HPLC: OD-H, 254 nm, *n*-hexane/isopropanol = 90: 10, flow rate 0.5 mL/min, 25 °C, t_r (minor) = 12.0 min, t_r (major) = 8.8 min); $[\alpha]_D^{20} = -17.4^\circ$ (*c* 1.0, CH₂Cl₂).

¹H NMR (500 MHz, CD₂Cl₂) δ 7.43-7.33 (m, 6H), 7.32-7.23 (m, 6H), 7.04 (td, $J = 7.8, 1.7$ Hz, 1H), 6.94-6.90 (m, 3H), 6.70 (d, $J = 8.5$ Hz, 1H), 6.66-6.60 (m, 2H), 6.27 (d, $J = 7.9$ Hz, 1H), 4.69 (d, $J = 14.8$ Hz, 1H), 3.64 (d, $J = 14.8$ Hz, 1H), 3.59 (br, 1H), 3.19-3.14 (m, 1H), 3.00-2.82 (m, 1H), 2.77-2.66 (m, 2H), 1.84-1.77 (m, 1H), 1.75-1.70 (m, 1H).

¹³C NMR (125 MHz, CD₂Cl₂) δ 149.9, 147.5, 145.6, 138.8, 138.5, 137.0, 130.3, 129.3, 128.5, 128.3 (2C), 128.2, 128.1, 127.3, 127.2, 127.1, 126.7, 126.0, 125.0, 124.1 (2C), 117.8, 114.0, 75.2, 64.7, 51.1, 28.0, 22.0.

IR (film): ν (cm⁻¹) 3060, 3023, 2929, 2841, 1671, 1600, 1575, 1493, 1482, 1444, 1343, 1326, 1301, 1191, 1171, 1137, 1097, 1063, 763, 739, 697, 675, 647, 563, 440.

HRMS (ESI, m/z) calcd for C₃₂H₃₀N₃O⁺ [M+H]⁺: 472.2383, found: 472.2386.



Starting from **1d** (48.9 mg, 0.15 mmol) and **2h** (63.9 mg, 0.225 mmol)


with Λ -**RhS** for 5 h according to the general procedure to give **3i** as a pale yellow solid (68.0 mg, 0.128 mmol, 85% yield). Enantiomeric excess established by HPLC analysis by using a Chiralpak OD-H column, ee = 91% (HPLC: OD-H, 254 nm, *n*-hexane/isopropanol = 90: 10, flow rate 0.5 mL/min, 25 °C, t_r (minor) = 8.9 min, t_r (major) = 8.4 min); $[\alpha]_D^{20} = +11.6^\circ$ (*c* 1.0, CH₂Cl₂).

¹H NMR (500 MHz, CD₂Cl₂) δ 7.40-7.34 (m, 2H), 7.31-7.24 (m, 5H), 7.23-7.19 (m, 5H), 7.00 (td, *J* = 8.1, 2.0 Hz, 1H), 6.91 (d, *J* = 8.3 Hz, 4H), 6.77 (d, *J* = 0.9 Hz, 1H), 6.60 (d, *J* = 8.3 Hz, 4H), 6.57 (d, *J* = 0.8 Hz, 1H), 6.19 (d, *J* = 7.8 Hz, 1H), 4.98 (d, *J* = 15.2 Hz, 1H), 4.40 (d, *J* = 15.2 Hz, 1H), 3.39 (s, 1H), 2.22 (s, 6H).

¹³C NMR (125 MHz, CD₂Cl₂) δ 149.3, 147.2, 144.6, 138.6, 138.5, 136.5, 131.2, 130.1, 129.3, 129.2, 128.3, 128.1, 127.9, 127.7, 127.1, 126.8, 126.7, 125.7, 125.1, 123.6, 121.7, 76.1, 64.0, 20.0.

IR (film): ν (cm⁻¹) 3057, 3026, 2977, 2858, 1687, 1507, 1482, 1439, 1341, 1302, 1264, 1172, 1137, 1101, 1069, 1010, 880, 811, 764, 736, 697, 676, 581, 565, 530, 444.

HRMS (ESI, *m/z*) calcd for C₃₇H₃₄N₃O⁺ [M+H]⁺: 536.2696, found: 536.2699.



Starting from **1d** (48.9 mg, 0.15 mmol) and **2i** (82.6 mg, 0.225 mmol)

with Λ -**RhS** for 30 h according to the general procedure to give **3j** as a white solid (64.0 mg, 0.104 mmol, 69% yield). Enantiomeric excess established by HPLC analysis by using a Chiralpak IA

column, ee = 93% (HPLC: IA, 254 nm, *n*-hexane/isopropanol = 95: 5, flow rate 0.3 mL/min, 25 °C, t_r (minor) = 18.3 min, t_r (major) = 20.3 min); $[\alpha]_D^{20} = +24.6^\circ$ (*c* 1.0, CH₂Cl₂).




¹H NMR (300 MHz, CDCl₃, mixture of two rotamers) δ 7.45-7.35 (m, 2H), 7.33-7.24 (m, 4H), 7.23-7.11 (m, 7H), 7.10 (br, 2H), 7.04-6.95 (m, 2H), 6.78 (d, *J* = 1.2 Hz, 1H), 6.75-6.66 (m, 4H), 6.58 (br, 1H), 6.19 (d, *J* = 7.6 Hz, 1H), 5.02 (d, *J* = 15.4 Hz, 0.2 H), 4.92 (d, *J* = 15.1 Hz, 0.8 H, other rotamer), 4.47 (d, *J* = 15.1 Hz, 0.8 H), 4.15 (d, *J* = 14.8 Hz, 0.2 H, other rotamer), 3.44 (br, 0.8 H), 3.27 (br, 0.2 H, other rotamer), 1.17 (s, 18H).

¹³C NMR (75 MHz, CDCl₃) δ 149.6, 146.9, 144.7, 144.5, 138.9, 138.7, 136.7, 130.3, 128.6, 128.5, 128.4, 128.1, 127.8, 127.7, 127.6, 127.3, 126.9, 126.8, 126.5, 126.1, 126.0, 125.7, 125.4, 123.7, 121.5, 75.9, 64.3, 34.0, 31.4.

IR (film): ν (cm⁻¹) 3058, 2959, 2902, 2865, 1603, 1509, 1483, 1445, 1393, 1363, 1303, 1266, 1201, 1172, 1138, 1100, 1068, 1011, 882, 826, 766, 736, 697, 677, 656, 609, 583, 571, 556.

HRMS (ESI, *m/z*) calcd for C₄₃H₄₆N₃O⁺ [M+H]⁺: 620.3635, found: 620.3643.

General procedure for Figure 3. A dried 10 mL Schlenk tube was charged with the catalyst Λ -**RhS** (5.20 mg, 0.0060 mmol, 4 mol%), the photosensitizer [Ru(bpy)₃](PF₆)₂ (1.30 mg, 0.0015 mmol, 1 mol%) and 2-acyl imidazole **1e-m** (0.150 mmol, 1.0 eq.). A solution of **2a** (87.0 mg, 0.450 mmol, 3.0 eq.) or **2j** (103 mg, 0.450 mmol, 3.0 eq.) in MeCN/DMAC (*v/v* = 4:1, 1 mL) was added in one portion. The reaction mixture was degassed *via* freeze-pump-thaw for three cycles. After the mixture was thoroughly degassed, the vial was sealed and positioned approximately 5 cm from a 23 W compact fluorescent lamp. The reaction was stirred at room temperature for the indicated time (monitored by TLC) under nitrogen atmosphere. Afterwards, the mixture was concentrated under reduced pressure. The residue was redissolved in THF (2 mL), then TBAF (1.0 mL, 1.0 M in THF, 1.0 mmol) was added. The mixture was stirred at room temperature for another 0.5 h and quenched by the addition of saturated aqueous solution of NH₄Cl, extracted by EtOAc (3 × 10 mL). The combined organic layers were concentrated. The residue was subjected to a flash chromatography on silica gel (EtOAc/*n*-hexane = 1:7 to 1:4) to afford the products **3k-s**. The enantiomeric excess was determined by chiral HPLC analysis.




Starting from **1e** (50.7 mg, 0.15 mmol) and **2a** (87.4 mg, 0.45 mmol) with $\Delta\text{-RhS}$ for 5h according to the general procedure to give **3k** as a white solid (51.6 mg, 0.113 mmol, 75% yield). Enantiomeric excess established by HPLC analysis by using a Chiralpak OD-H column, ee = 98% (HPLC: OD-H, 254 nm, *n*-hexane/isopropanol = 95: 5, flow rate 0.5 mL/min, 25 °C, t_r (minor) = 14.8 min, t_r (major) = 10.6 min); $[\alpha]_D^{20} = -40.0^\circ$ (*c* 1.0, CH₂Cl₂).

¹H NMR (500 MHz, CD₂Cl₂, mixture of rotamers) δ 7.41-7.37 (m, 2H), 7.30-7.20 (m, 6H), 7.19-7.14 (m, 4H), 7.10-7.07 (m, 1H), 6.92 (d, J = 1.0 Hz, 1H), 6.81 (d, J = 8.2 Hz, 2H), 6.74 (t, J = 7.3 Hz, 1H), 6.64 (d, J = 0.9 Hz, 1H), 6.41 (d, J = 7.8 Hz, 1H), 4.63 (d, J = 14.7 Hz, 0.8 H), 4.46 (d, J = 14.7 Hz, 0.2 H, other rotamer), 3.64 (d, J = 14.7 Hz, 1H), 3.42 (br, 0.8 H), 3.32 (br, 0.2 H, other rotamer), 2.66 (s, 2.4 H), 2.56 (s, 0.6 H, other rotamer), 2.36 (s, 2.4 H), 2.28 (s, 0.6 H, other rotamer).

¹³C NMR (125 MHz, CD₂Cl₂) δ 152.2, 150.2, 142.6, 139.1, 139.0, 137.6, 137.3, 130.6, 129.3, 129.1, 128.8, 128.7, 128.6, 128.5, 127.6, 127.5, 126.4, 125.3, 124.5, 118.5, 114.4, 75.9, 65.7, 39.2, 21.1.

IR (film): ν (cm⁻¹) 3059, 3026, 2921, 2867, 2813, 1598, 1503, 1482, 1438, 1411, 1351, 1303, 1252, 1172, 1139, 1113, 1088, 1034, 992, 952, 927, 915, 816, 765, 735, 695, 559, 469.

HRMS (ESI, m/z) calcd for C₃₁H₃₀N₃O⁺ [M+H]⁺: 460.2383, found: 460.2387.



Starting from **1f** (50.7 mg, 0.15 mmol) and **2a** (87.4 mg, 0.45 mmol) with

Λ -**RhS** for 5h according to the general procedure to give **31** as a white solid (55.0 mg, 0.12 mmol, 80% yield). Enantiomeric excess established by HPLC analysis by using a Chiralpak OD-H column, ee = 97% (HPLC: OD-H, 254 nm, *n*-hexane/isopropanol = 90: 10, flow rate 0.5 mL/min, 25 °C, t_r (minor) = 11.7 min, t_r (major) = 10.3 min); $[\alpha]_D^{20} = -18.2^\circ$ (c 1.0, CH₂Cl₂).


¹H NMR (500 MHz, CD₂Cl₂, mixture of rotamers) δ 7.40-7.38 (m, 2H), 7.28-7.20 (m, 5H), 7.18-7.04 (m, 6H), 6.92 (d, J = 0.7 Hz, 1H), 6.81 (d, J = 8.1 Hz, 2H), 6.74 (t, J = 7.3 Hz, 1H), 6.64 (d, J = 0.9 Hz, 1H), 6.38 (d, J = 7.9 Hz, 1H), 4.65 (d, J = 14.8 Hz, 0.8 H), 4.52 (d, J = 14.3 Hz, 0.2 H, other rotamer), 3.67 (d, J = 14.7 Hz, 1H), 3.46 (br, 0.8 H), 3.43 (br, 0.2 H, other rotamer), 2.66 (s, 2.4 H), 2.56 (s, 0.6 H, other rotamer), 2.33 (s, 2.4 H), 2.21 (s, 0.6 H, other rotamer).

¹³C NMR (75 MHz, CD₂Cl₂) δ 152.2, 150.1, 145.5, 139.1, 139.0, 138.4, 137.5, 130.6, 129.1, 128.9,

128.7, 128.6, 128.5 (2C), 128.3, 128.1, 127.6, 127.4, 126.4, 126.0, 124.5, 122.5, 118.5, 114.4, 75.8, 65.7, 39.3, 21.7.

IR (film): ν (cm⁻¹) 3055, 3025, 2920, 2861, 1598, 1503, 1482, 1438, 1350, 1303, 1256, 1180, 1034, 992, 942, 788, 747, 736, 695, 676, 649, 609, 556, 514, 438.

HRMS (ESI, m/z) calcd for C₃₁H₃₀N₃O⁺ [M+H]⁺: 460.2383, found: 460.2386.



Starting from **1g** (53.8 mg, 0.15 mmol) and **2a** (87.4 mg, 0.45 mmol) with Λ -**RhS**


for 5h according to the general procedure to give **3m** as a white solid (63.2 mg, 0.13 mmol, 88% yield). Enantiomeric excess established by HPLC analysis by using a Chiralpak OD-H column, ee = 93% (HPLC: OD-H, 254 nm, *n*-hexane/isopropanol = 90: 10, flow rate 1.0 mL/min, 25 °C, t_r (minor) = 6.5 min, t_r (major) = 5.0 min); $[\alpha]_D^{20} = +11.4^\circ$ (*c* 1.0, CH₂Cl₂).

¹H NMR (500 MHz, CD₂Cl₂) δ 7.44-7.43 (m, 2H), 7.37-7.31 (m, 4H), 7.29-7.23 (m, 5H), 7.22-7.19 (m, 3H), 7.17-7.12 (m, 1H), 7.01 (d, *J* = 1.2 Hz, 1H), 6.82-6.80 (m, 3H), 6.72 (d, *J* = 1.2 Hz, 1H), 6.45 (d, *J* = 7.8 Hz, 1H), 4.67 (d, *J* = 14.8 Hz, 1H), 3.63 (d, *J* = 14.8 Hz, 1H), 3.54 (s, 1H), 2.64 (s, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 151.5, 149.3, 143.5, 138.8, 138.6, 136.9, 133.1, 130.4, 129.0 (2C), 128.8, 128.4, 128.3, 128.0, 127.4, 127.2, 126.5, 126.4, 124.4, 118.7, 114.3, 75.0, 65.2, 39.0.

IR (film): ν (cm⁻¹) 3137, 2923, 2853, 1652, 1583, 1568, 1504, 1481, 1445, 1434, 1395, 1341, 1305, 1280, 1256, 1233, 1165, 1141, 1084, 1011, 928, 872, 794, 755, 737, 721, 695, 653, 612, 593, 550, 497, 427.

HRMS (ESI, m/z) calcd for C₃₀H₂₇ClN₃O⁺ [M+H]⁺: 480.1837, found: 480.1835.



Starting from **1h** (57.3 mg, 0.15 mmol) and **2a** (87.4 mg, 0.45 mmol) with


Λ -**RhS** for 5h according to the general procedure to give **3n** as a white solid (59.1 mg, 0.118 mmol, 79% yield). Enantiomeric excess established by HPLC analysis by using a Chiralpak OD-H column, ee = 54% (HPLC: OD-H, 254 nm, *n*-hexane/isopropanol = 90: 10, flow rate 1.0 mL/min, 25 °C, t_r (minor) = 6.1 min, t_r (major) = 4.8 min); $[\alpha]_D^{20} = -6^\circ$ (*c* 1.0, CH₂Cl₂).

¹H NMR (500 MHz, CD₂Cl₂, mixture of rotamers) δ 8.00 (d, *J* = 8.4 Hz, 2H), 7.76 (d, *J* = 8.1 Hz, 2H, other rotamer), 7.48 (d, *J* = 8.4 Hz, 2H), 7.43-7.38 (m, 2H), 7.37-7.31 (m, 1H), 7.23-7.20 (m, 3H), 7.19-7.16 (m, 2H), 7.09-7.06 (m, 1H), 7.02 (br, 1H), 6.81 (t, *J* = 8.2 Hz, 1H), 6.82-6.76 (m, 3H), 6.70 (br, 1H), 6.34 (d, *J* = 7.8 Hz, 1H), 4.71 (d, *J* = 15.0 Hz, 0.8 H), 4.51 (d, *J* = 14.8 Hz, 0.2 H, other rotamer), 3.93 (s, 3H), 3.65 (d, *J* = 14.6 Hz, 1H), 3.60 (br, 1H), 2.60 (s, 2.4 H), 2.57 (s, 0.6 H, other rotamer).

¹³C NMR (125 MHz, CDCl₃) δ 167.0, 151.6, 149.2, 139.0, 138.7, 136.9, 130.5, 129.8, 129.3, 129.1, 129.0, 128.4 (2C), 128.0, 127.5, 127.4, 126.5, 125.5, 125.2, 124.6, 118.9, 114.4, 75.3, 65.2, 52.2, 39.2.

IR (film): ν (cm⁻¹) 2953, 2897, 2807, 1722, 1599, 1504, 1441, 1410, 1362, 1275, 1246, 1186, 1106, 846, 743, 693, 516.

HRMS (ESI, *m/z*) calcd for C₃₂H₂₉N₃NaO₃⁺ [M+Na]⁺: 526.2101, found: 526.2101.




Starting from **1i** (53.1 mg, 0.15 mmol) and **2a** (87.4 mg, 0.45 mmol) with Λ -**RhS** for 15h according to the general procedure to give **3o** as a white solid (50.5 mg, 0.106 mmol, 71% yield). Enantiomeric excess established by HPLC analysis by using a Chiralpak OD-H column, ee = 86% (HPLC: OD-H, 254 nm, *n*-hexane/isopropanol = 90: 10, flow rate 1.0 mL/min, 25 °C, t_r (minor) = 7.5 min, t_r (major) = 5.8 min); $[\alpha]_D^{20} = -33^\circ$ (*c* 1.0, CH₂Cl₂).

¹H NMR (500 MHz, CD₂Cl₂, mixture of rotamers) δ 7.44-7.38 (m, 2H), 7.33-7.22 (m, 6H), 7.17 (dd, $J = 7.3, 1.3$ Hz, 2H), 7.11-7.08 (m, 1H), 7.00-6.90 (m, 3H), 6.83-6.80 (m, 3H), 6.74 (t, $J = 7.3$ Hz, 1H), 6.64 (d, $J = 0.9$ Hz, 1H), 6.41 (d, $J = 7.9$ Hz, 1H), 4.66 (d, $J = 14.8$ Hz, 0.8 H), 4.52 (d, $J = 14.4$ Hz, 0.2 H, other rotamer), 3.76 (s, 2.4 H), 3.67 (d, $J = 14.8$ Hz, 1H), 3.65 (s, 0.6 H, other rotamer), 3.50 (br, 1H), 2.66 (s, 2.4 H), 2.58 (s, 0.6 H, other rotamer).

¹³C NMR (125 MHz, CDCl₃) δ 159.8, 151.8, 149.7, 146.9, 138.8, 137.1, 130.3, 129.3, 128.8, 128.5, 128.3, 128.2, 127.3, 127.1, 126.1, 124.2, 118.3, 117.4, 114.1, 112.7, 110.5, 75.3, 65.3, 55.2, 38.9.

IR (film): ν (cm⁻¹) 3059, 2925, 2862, 1599, 1503, 1445, 1413, 1352, 1301, 1246, 1172, 1085, 1031, 951, 828, 737, 695, 559, 521, 470.

HRMS (ESI, *m/z*) calcd for C₃₁H₂₉N₃NaO₂⁺ [M+Na]⁺: 498.2152, found: 498.2148.



Starting from **1j** (57.3 mg, 0.15 mmol) and **2a** (87.4 mg, 0.45 mmol) with Λ -**RhS** for 15h according to the general procedure to give **3p** as a pale yellow oil (60.4 mg, 0.120


mmol, 80% yield). Enantiomeric excess established by HPLC analysis by using a Chiralpak OD-H column, ee = 96% (HPLC: OD-H, 254 nm, *n*-hexane/isopropanol = 90: 10, flow rate 1.0 mL/min, 25 °C, t_r (minor) = 9.4 min, t_r (major) = 7.2 min); $[\alpha]_D^{20} = -40^\circ$ (*c* 1.0, CH₂Cl₂).

¹H NMR (500 MHz, CDCl₃, mixture of rotamers) 7.44-7.40 (m, 3H), 7.34-7.32 (m, 1H), 7.28-7.19 (m, 6H), 7.16-7.10 (m, 1H), 7.09-7.06 (m, 2H), 7.00 (br, 1H), 6.88-6.74 (m, 4H), 6.70 (d, *J* = 1.1 Hz, 1H), 6.45 (d, *J* = 7.9 Hz, 1H), 4.70 (d, *J* = 14.7 Hz, 0.75 H), 4.45 (d, *J* = 14.1 Hz, 0.25 H, other rotamer), 3.67 (d, *J* = 14.8 Hz, 1H), 3.57 (br, 1H), 2.66 (s, 2.25 H), 2.60 (s, 0.75 H, other rotamer), 2.34 (s, 2.25 H), 2.31 (s, 0.75 H, other rotamer).

¹³C NMR (125 MHz, CDCl₃) δ 169.4, 151.6, 149.9, 149.6, 138.8, 138.7, 130.3, 129.0 (2C), 128.8, 128.3 (2C), 128.2, 128.0, 127.4, 127.3, 126.5, 126.2, 124.4, 121.4, 118.7, 114.3, 75.1, 65.2, 39.0, 21.2.

IR (film): ν (cm⁻¹) 3059, 2925, 2869, 1757, 1598, 1499, 1443, 1363, 1304, 1256, 1195, 1116, 1084, 1012, 954, 909, 845, 737, 695, 554, 521.

HRMS (ESI, *m/z*) calcd for C₃₂H₂₉N₃NaO₃⁺ [M+Na]⁺: 526.2101, found: 526.2098.



Starting from **1k** (60.0 mg, 0.15 mmol) and **2a** (87.4 mg, 0.45 mmol) with Λ -**RhS**

for 15 h according to the general procedure to give **3q** as a white solid (46.4 mg, 0.105 mmol, 70% yield). Enantiomeric excess established by HPLC analysis by using a Chiralpak OD-H column, ee = 96% (HPLC: OD-H, 254 nm, hexane/isopropanol = 90: 10, flow rate 0.5 mL/min, 25 °C, t_r (minor) = 16.5 min, t_r (major) = 11.5 min); $[\alpha]_D^{20} = -26.2^\circ$ (*c* 1.0, CH₂Cl₂).


¹H NMR (500 MHz, CD₂Cl₂, mixture of rotamers) δ 7.69 (d, *J* = 7.7 Hz, 2H), 7.64 (d, *J* = 8.4, 2H), 7.51-7.43 (m, 5H), 7.42-7.27 (m, 6H), 7.22 (t, *J* = 8.7 Hz, 2H), 7.16-7.12 (m, 1H), 7.00 (d, *J* = 1.1

Hz, 1H) 6.87 (d, $J = 8.4$ Hz, 2H), 6.79 (t, $J = 7.4$ Hz, 1H), 6.72 (d, $J = 1.0$, 1H), 6.51 (d, $J = 8.0$, 1H), 4.74 (d, $J = 14.8$ Hz, 0.8 H), 4.51 (d, $J = 14.8$ Hz, 0.2 H, other rotamer), 3.74 (d, $J = 14.7$ Hz, 1H), 3.57 (br, 0.8 H), 3.43 (br, 0.2 H, other rotamer), 2.72 (s, 2.4 H), 2.63 (s, 0.6 H, other rotamer).

^{13}C NMR (125 MHz, CD_2Cl_2) δ 152.2, 150.0, 144.6, 140.9, 140.2, 139.1 (2C), 137.5, 130.7, 129.2, 129.1, 128.9, 128.7, 128.6 (2C), 127.7, 127.6, 127.3, 127.2, 126.6, 125.9, 124.6, 118.6, 114.5, 75.8, 65.7, 39.3.

IR (film): ν (cm^{-1}) 3383, 3060, 2967, 2878, 1597, 1494, 1446, 1366, 1303, 1268, 1193, 1161, 1132, 1104, 1070, 951, 740, 696, 608, 533, 457.

HRMS (ESI, m/z) calcd for $\text{C}_{36}\text{H}_{32}\text{N}_3\text{O}^+$ $[\text{M}+\text{H}]^+$: 522.2540, found: 522.2543.



Starting from **11** (40.8 mg, 0.15 mmol) and **2a** (87.4 mg, 0.45 mmol) with

Λ -**RhS** for 5h according to the general procedure to give **3r** as a white solid (52.4 mg, 0.132 mmol, 88% yield). Enantiomeric excess established by HPLC analysis by using a Chiralpak OD-H column, ee = 97% (HPLC: OD-H, 254 nm, *n*-hexane/isopropanol = 95: 5, flow rate 0.5 mL/min, 25 °C, t_r (minor) = 19.2 min, t_r (major) = 15.9 min); $[\alpha]_{\text{D}}^{20} = +19.2^\circ$ (c 1.0, CH_2Cl_2).


^1H NMR (300 MHz, CDCl_3 , mixture of rotamers) δ 7.52-7.46 (m, 1H), 7.44-7.32 (m, 2H), 7.30-7.24 (m, 2H), 7.23-7.18 (m, 2H), 7.17-7.11 (m, 4H), 7.09 (d, $J = 1.1$ Hz, 1H), 7.03 (d, $J = 1.1$ Hz, 1H, other rotamer), 6.95-6.91 (m, 1H), 6.70 (dd, $J = 12.5, 6.9$ Hz, 1H), 6.62 (d, $J = 8.3$ Hz, 1H), 6.51 (d, $J = 8.3$ Hz, 1H), 3.64 (d, $J = 14.8$ Hz, 0.4 H), 3.55 (d, $J = 14.9$ Hz, 0.6 H, other rotamer), 3.47 (d, $J = 14.8$ Hz, 0.4 H), 3.39 (d, $J = 14.9$ Hz, 0.6 H, other rotamer), 2.70 (br, 0.4 H), 2.62 (s, 1.8 H), 2.42 (s, 1.2 H, other rotamer), 2.26 (br, 0.6 H, other rotamer), 1.86-1.73 (m, 1.2 H), 1.58-1.48 (m, 0.8 H, other rotamer), 0.67 (t, $J = 7.5$ Hz, 1.2 H), 0.40 (t, $J = 7.4$ Hz, 1.8 H, other rotamer).

^{13}C NMR (125 MHz, CDCl_3 , mixture of rotamers) δ 151.5, 150.8, 150.6, 150.3, 139.7 (2C), 138.6,

138.5, 137.7, 137.4, 130.9, 130.6, 129.1, 129.0 (2C), 128.8, 128.7, 128.6, 128.5, 128.4, 127.9, 127.7, 127.6, 127.5, 127.0, 126.7, 124.9, 124.6, 117.4, 117.2, 113.4, 112.8, 78.2, 64.5, 64.3, 39.8, 39.1, 33.7, 31.3, 8.0, 6.8.

IR (film): ν (cm⁻¹) 3060, 2965, 2932, 2874, 1598, 1504, 1481, 1439, 1371, 1330, 1303, 1277, 1256, 1213, 1191, 1166, 1129, 1118, 1100, 1025, 989, 926, 879, 761, 700, 692, 610, 556, 526, 484.

HRMS (ESI, m/z) calcd for C₂₆H₂₈N₃O⁺ [M+H]⁺: 398.2227, found: 398.2226.



Starting from **1m** (39.3 mg, 0.15 mmol) and **2j** (103 mg, 0.45 mmol) with Λ -**RhS** for 15h according to the general procedure to give **3s** as a white solid (54.2 mg, 0.130 mmol, 86% yield). Enantiomeric excess established by HPLC analysis by using a Chiralpak OD-H column, ee = 99% (HPLC: OD-H, 254 nm, *n*-hexane/isopropanol = 90: 10, flow rate 1.0 mL/min, 25 °C, t_r (minor) = 8.3 min, t_r (major) = 7.4 min); $[\alpha]_D^{20} = -8.2^\circ$ (*c* 1.0, CH₂Cl₂).

¹H NMR (300 MHz, CDCl₃, mixture of rotamers) δ 7.58-7.47 (m, 2H), 7.46-7.27 (m, 3H), 7.26-7.09 (m, 4H), 7.07-7.01 (m, 1H), 6.99 (dd, $J = 8.0, 1.2$ Hz, 1H), 6.92 (dd, $J = 13.2, 1.2$ Hz, 1H), 6.62 (dt, $J = 7.8, 1.8$ Hz, 1H), 6.56 (dt, $J = 12.2, 2.4$ Hz, 1H), 6.47 (qd, $J = 17.7, 8.5, 2.4$ Hz, 1H), 3.60-3.50 (m, 1H), 3.48-3.28 (m, 1H), 3.00 (br, 0.6 H), 2.65 (s, 1.8 H), 2.60 (s, 1.2 H, other rotamer), 2.30 (br, 0.4 H, other rotamer), 1.23 (s, 1.2 H), 1.13 (s, 1.8 H, other rotamer).

¹³C NMR (75 MHz, CD₂Cl₂, mixture of rotamers) δ 152.4, 152.2, 151.7, 151.3, 140.1, 140.0, 138.8, 138.7, 137.8, 137.6, 135.1, 134.9, 131.4, 131.0, 130.2, 130.1, 129.8, 129.6, 129.0, 128.8 (3C), 128.3 (2C), 128.2, 128.1, 127.4, 126.8, 125.3, 124.8, 116.9, 116.7, 112.9, 112.8, 111.4, 111.3, 75.7, 74.8, 64.8, 63.4, 40.0 (2C), 26.5, 26.3.

IR (film): ν (cm⁻¹) 2971, 2918, 2849, 1594, 1558, 1497, 1481, 1373, 1339, 1308, 1263, 1195, 1179, 1126, 1098, 1080, 1001, 988, 979, 948, 921, 819, 773, 762, 752, 732, 699, 675, 603, 572, 546, 499, 442.

HRMS (ESI, m/z) calcd for $C_{25}H_{25}ClN_3O^+$ $[M+H]^+$: 418.1681, found: 418.1684.


4. Chiral Chromatography

Enantiomeric purities of the compounds **3a-s** were determined with a Daicel Chiralpak IA, OD-H or AD-H (250 × 4.6 mm) HPLC column on an Agilent 1200, 1260 or Shimadzu Lc-2030c HPLC system by using *n*-hexane/isopropanol as mobile phase, column temperature = 25 °C, UV-absorption was measured at 254 nm.


4.1. Enantioselectivities of Catalytic Reactions in Table 1

<Chromatogram>

mV



mV



<Peak Table>


Detector A 254nm

| Peak# | Ret. Time | Area% | Height% |
|-------|-----------|---------|---------|
| 1 | 9.596 | 29.371 | 20.946 |
| 2 | 11.204 | 70.629 | 79.054 |
| Total | | 100.000 | 100.000 |


Figure S1. HPLC traces of *rac*-**3a'** (reference) and (*S*)-**3a'** for entry 1 (Table 1). Area integration = 70.6:29.4 (41.2% ee).

<Chromatogram>

mV



mV





<Peak Table>

Detector A 254nm



| Peak# | Ret. Time | Height | Area% |
|-------|-----------|--------|---------|
| 1 | 15.209 | 162937 | 70.663 |
| 2 | 20.362 | 46930 | 29.337 |
| Total | | 209867 | 100.000 |

Figure S2. HPLC traces of *rac*-**3a** (reference) and (*S*)-**3a** for entry 2 (Table 1). Area integration = 70.7:29.3 (41.4% ee).



| Peak # | RetTime [min] | Type | Width [min] | Area mAU *s | Height [mAU] | Area % |
|--------|---------------|------|-------------|-------------|--------------|---------|
| 1 | 9.861 | BB | 0.2660 | 1.03046e4 | 574.54633 | 90.9323 |
| 2 | 14.051 | MM | 0.4476 | 1027.56458 | 38.26324 | 9.0677 |

Figure S3. HPLC traces of *rac*-**3b** (reference) and (*S*)-**3b** for entry 3 (Table 1). Area integration = 90.9:9.1 (81.8% ee).





| Peak # | RetTime [min] | Type | Width [min] | Area [mAU*s] | Height [mAU] | Area % |
|--------|---------------|------|-------------|--------------|--------------|---------|
| 1 | 12.263 | BB | 0.2140 | 179.30820 | 10.13283 | 6.1965 |
| 2 | 13.696 | BV R | 0.3174 | 2714.38672 | 127.20956 | 93.8035 |

Figure S4. HPLC traces of *rac*-**3c** (reference) and (*S*)-**3c** for entry 4 (Table 1). Area integration = 93.8:6.2 (87.6% ee).

<Chromatogram>

mV




| Peak # | RetTime [min] | Type | Width [min] | Area [mAU*s] | Height [mAU] | Area % |
|--------|---------------|------|-------------|--------------|--------------|---------|
| 1 | 13.272 | BB | 0.3314 | 4766.38721 | 219.01707 | 96.2819 |
| 2 | 15.849 | BB | 0.3159 | 184.06299 | 6.81893 | 3.7181 |

Figure S5. HPLC traces of *rac*-**3d** (reference) and (*S*)-**3d** for entry 5 (Table 1). Area integration = 96.3:3.7 (92.6% ee).

<Chromatogram>


mV



Detector A 254nm

| Peak# | Ret. Time | Area | Height | Area% |
|-------|-----------|----------|--------|---------|
| 1 | 13.270 | 9890583 | 241364 | 97.402 |
| 2 | 15.138 | 263857 | 9359 | 2.598 |
| Total | | 10154440 | 250723 | 100.000 |



Figure S6. HPLC traces of (S)-**3d** for entry 8 (Table 1). Area integration = 97.4:2.6 (94.8% ee).



| Peak # | RetTime [min] | Type | Width [min] | Area [mAU*s] | Height [mAU] | Area % |
|--------|---------------|------|-------------|--------------|--------------|---------|
| 1 | 12.761 | MM | 0.3782 | 3386.37866 | 149.22783 | 89.5951 |
| 2 | 15.429 | MM | 0.4466 | 393.27032 | 14.67682 | 10.4049 |



Figure S7. HPLC traces of (S)-**3d** for entry 11 (Table 1). Area integration = 89.6:10.4 (79% ee).

4.2. Enantioselectivities of Catalytic Reactions in Figure 2





| Peak # | RetTime [min] | Type | Width [min] | Area [mAU*s] | Height [mAU] | Area % |
|--------|---------------|------|-------------|--------------|--------------|---------|
| 1 | 5.980 | FM | 0.1774 | 3260.22437 | 306.32999 | 98.7895 |
| 2 | 9.917 | MM | 0.3193 | 39.94799 | 2.08492 | 1.2105 |

Figure S8. HPLC traces of *rac*-**3e** (reference) and (*S*)-**3e**. Area integration = 98.8:1.2 (97.6% ee).





| Peak # | RetTime [min] | Type | Width [min] | Area mAU *s | Height [mAU] | Area % |
|--------|---------------|------|-------------|-------------|--------------|---------|
| 1 | 6.015 | BB | 0.1547 | 2029.23083 | 193.00230 | 98.4628 |
| 2 | 6.831 | BB | 0.1502 | 31.68109 | 2.84675 | 1.5372 |

Figure S9. HPLC traces of *rac*-**3f** (reference) and (*S*)-**3f**. Area integration = 98.5:1.5 (97.0% ee).





| Peak # | RetTime [min] | Type | Width [min] | Area mAU *s | Height [mAU] | Area % |
|--------|---------------|------|-------------|-------------|--------------|---------|
| 1 | 10.043 | MM | 0.2391 | 9083.17383 | 633.03650 | 96.4320 |
| 2 | 11.169 | MM | 0.2989 | 336.08112 | 18.74218 | 3.5680 |

Figure S10. HPLC traces of *rac*-**3g** (reference) and (*S*)-**3g**. Area integration = 96.4:3.6 (92.8% ee).



| Peak # | RetTime [min] | Type | Width [min] | Area mAU | Area *s | Height [mAU] | Area % |
|--------|---------------|------|-------------|------------|---------|--------------|---------|
| 1 | 8.795 | VV | 0.4384 | 8384.35840 | | 316.73041 | 97.5180 |
| 2 | 12.004 | MM | 0.2793 | 213.39981 | | 12.73467 | 2.4820 |

Figure S11. HPLC traces of *rac*-**3h** (reference) and (*S*)-**3h**. Area integration = 97.5:2.5 (95% ee).




| Peak # | RetTime [min] | Type | Width [min] | Area mAU *s | Height [mAU] | Area % |
|--------|---------------|------|-------------|-------------|--------------|---------|
| 1 | 8.370 | MM | 0.1740 | 1.38711e4 | 1328.44141 | 95.4270 |
| 2 | 8.945 | MM | 0.1901 | 664.72369 | 58.27687 | 4.5730 |

Figure S12. HPLC traces of *rac*-**3i** (reference) and (*S*)-**3i**. Area integration = 95.4:4.6 (90.8% ee).


<Chromatogram>

mV



<Chromatogram>

mV





Detector A 254nm

| Peak# | Ret. Time | Area | Height | Area% |
|-------|-----------|---------|--------|---------|
| 1 | 18.290 | 254320 | 11956 | 3.378 |
| 2 | 20.348 | 7273575 | 331402 | 96.622 |
| Total | | 7527895 | 343358 | 100.000 |



Figure S13. HPLC traces of *rac*-**3j** (reference) and (*S*)-**3j**. Area integration = 96.6:3.4 (93.2% ee).

4.3. Enantioselectivities of Catalytical Reactions in Figure 3



| Peak # | RetTime [min] | Type | Width [min] | Area mAU | Height [mAU] | Area % |
|--------|---------------|------|-------------|------------|--------------|---------|
| 1 | 10.333 | MM | 0.2822 | 3707.48926 | 218.97369 | 98.8361 |
| 2 | 11.731 | MM | 0.3151 | 43.65955 | 2.30919 | 1.1639 |

Figure S14. HPLC traces of *rac*-**3k** (reference) and (*S*)-**3k**. Area integration = 98.8:1.2 (97.6% ee).




| Peak # | RetTime [min] | Type | Width [min] | Area [mAU*s] | Height [mAU] | Area % |
|--------|---------------|------|-------------|--------------|--------------|---------|
| 1 | 10.600 | BB | 0.1646 | 5755.83105 | 556.66669 | 98.4809 |
| 2 | 14.773 | MM | 0.5538 | 88.78605 | 2.67200 | 1.5191 |

Figure S15. HPLC traces of *rac*-**31** (reference) and (*S*)-**31**. Area integration = 98.5:1.5 (97.0% ee).


<Chromatogram>

mV



<Chromatogram>



mV



Detector A 254nm

| Peak# | Ret. Time | Area | Area% |
|-------|-----------|--------|---------|
| 1 | 4.966 | 834381 | 96.258 |
| 2 | 6.463 | 32437 | 3.742 |
| Total | | 866818 | 100.000 |

Figure S16. HPLC traces of *rac*-**3m** (reference) and (*S*)-**3m**. Area integration = 96.3:3.7 (92.6% ee).




<Peak Table>

Detector A 254nm

| Peak# | Ret. Time | Area | Area% |
|-------|-----------|---------|---------|
| 1 | 4.805 | 1119561 | 77.019 |
| 2 | 6.146 | 334063 | 22.981 |
| Total | | 1453624 | 100.000 |



Figure S17. HPLC traces of *rac*-**3n** (reference) and (*S*)-**3n**. Area integration = 77:23 (54% ee).



<Peak Table>



| Detector A 254nm | | | |
|------------------|-----------|---------|---------|
| Peak# | Ret. Time | Area | Area% |
| 1 | 5.777 | 2376310 | 92.861 |
| 2 | 7.457 | 182679 | 7.139 |
| Total | | 2558989 | 100.000 |

Figure S18. HPLC traces of *rac*-**3o** (reference) and (*S*)-**3o**. Area integration = 92.9: 7.1 (85.8% ee).



| Peak # | RetTime [min] | Type | Width [min] | Area mAU | Height [mAU] | Area % |
|--------|---------------|------|-------------|-----------|--------------|---------|
| 1 | 7.204 | MF | 0.2382 | 693.82043 | 48.54126 | 98.0812 |
| 2 | 9.390 | MM | 0.4197 | 13.57364 | 5.39016e-1 | 1.9188 |

Figure S19. HPLC traces of *rac*-**3p** (reference) and (*S*)-**3p**. Area integration = 98:2 (96% ee).




| Peak # | RetTime [min] | Type | Width [min] | Area mAU | Height [mAU] | Area % |
|--------|---------------|------|-------------|------------|--------------|---------|
| 1 | 11.519 | VV | 0.3146 | 5945.34229 | 285.11261 | 98.3250 |
| 2 | 16.492 | MM | 0.5240 | 101.27905 | 3.22156 | 1.6750 |

Figure S20. HPLC traces of *rac*-**3q** (reference) and (*S*)-**3q**. Area integration = 98.3:1.7 (96.6% ee).


<Chromatogram>

mV



<Chromatogram>

mV




Detector A 254nm

| Peak# | Ret. Time | Area | Area% |
|-------|-----------|---------|---------|
| 1 | 15.851 | 4882967 | 98.579 |
| 2 | 19.157 | 70398 | 1.421 |
| Total | | 4953365 | 100.000 |

Figure S21. HPLC traces of *rac*-**3r** (reference) and (*S*)-**3r**. Area integration = 98.6:1.4 (97.2% ee).


<Chromatogram>

mV



<Chromatogram>

mV



<Peak Table>


Detector A 254nm

| Peak# | Ret. Time | Area | Area% |
|-------|-----------|---------|---------|
| 1 | 7.415 | 1812156 | 99.610 |
| 2 | 8.325 | 7102 | 0.390 |
| Total | | 1819258 | 100.000 |


Figure S22. HPLC traces of *rac*-**3s** (reference) and (*S*)-**3s**. Area integration = 99.6:0.4 (99.2% ee).

5. Mechanistic Studies

5.1 α -Amino Radical Trapping Experiments



A dried 10 mL Schlenk tube was charged with the photosensitizer [Ru(bpy)₃](PF₆)₂ (0.86 mg, 0.001 mmol, 1 mol%) and the 2-acyl imidazole **1a** (0.10 mmol, 1.0 eq.). A solution of **2a** (58.0 mg, 0.30 mmol, 3.0 eq.) or **2c** (36.4 mg, 0.30 mmol, 3.0 eq.) in MeCN/DMAC (v/v = 4:1, 1 mL) was added in one portion. The reaction mixture was degassed *via* freeze-pump-thaw for three cycles. After the mixture was thoroughly degassed, the vial was sealed and positioned approximately 5 cm from a 23 W compact fluorescent lamp. The reaction was stirred at room temperature for 15h under nitrogen atmosphere. Afterwards, the mixture was concentrated under reduced pressure. With **2a**, the residue was subjected to a flash chromatography on silica gel (EtOAc/*n*-hexane = 1:20 to 1:10) to afford the product **3a'** (11.3 mg, 0.030 mmol, 30% yield). With **2c**, no product was formed.




A dried 10 mL Schlenk tube was charged with the photosensitizer [Ru(bpy)₃](PF₆)₂ (0.86 mg, 0.001 mmol, 1 mol%) and the 2-acyl imidazole **1a** (0.10 mmol, 1.0 eq.). A solution of **2a** (58.0 mg, 0.30 mmol, 3.0 eq.) or **2c** (36.4 mg, 0.30 mmol, 3.0 eq.) in MeCN/DMAC (v/v = 4:1, 1 mL) was added

in one portion, followed by the addition of Diethyl 2-ethylidenemalonate (18 μ L, 0.1 mmol, 1 eq.). The reaction mixture was degassed *via* freeze-pump-thaw for three cycles. After the mixture was thoroughly degassed, the vial was sealed and positioned approximately 5 cm from a 23 W compact fluorescent lamp. The reaction was stirred at room temperature for 15h under nitrogen atmosphere. Afterwards, the reaction was quenched by the addition of saturated aqueous NH_4Cl solution, then extracted by EtOAc (3×10 mL). The organic layer was collected and concentrated under reduced pressure. The residue was subjected to a flash chromatography on silica gel (EtOAc/*n*-hexane = 1:20 to 1:10) to afford the product **4** (with **2a**: 27.0 mg, 0.055 mmol, 55% yield; with **2c**: 24.6 mg, 0.050 mmol, 50% yield).

^1H NMR (300 MHz, C_6D_6) δ 7.28-7.21 (m, 2H), 7.10-7.00 (m, 2H), 6.76-6.70 (m, 1H), 4.02-3.86 (m, 8H), 3.81 (dd, $J = 14.3, 5.1$ Hz, 1H), 3.68 (dd, $J = 14.6, 6.9$ Hz, 1H), 3.43 (d, $J = 6.5$ Hz, 1H), 3.36 (d, $J = 6.8$ Hz, 1H), 3.32 (dd, $J = 14.6, 8.1$ Hz, 1H), 3.13 (dd, $J = 14.3, 9.2$ Hz, 1H), 3.05-2.93 (m, 2H), 1.021 (d, $J = 7.0$ Hz, 3H), 1.017 (d, $J = 6.8$ Hz, 3H), 0.94-0.87 (m, 12H).

All spectroscopic data were in agreement with the literature.⁴

5.2 Synthesis of the Intermediate Complex I



The racemic complex **I** was obtained by reacting substrate **2a** (13.0 mg, 0.049 mmol) with *rac*-**RhS** (40.0 mg, 0.043 mmol) at room temperature for 10 min in CH₂Cl₂ (1.0 mL). After the slow addition of *n*-hexane (5.0 mL), crystals were collected after several days (32.2 mg, yield: 68%).

¹H NMR (500 MHz, CD₂Cl₂) δ 7.92 (dd, $J = 8.5, 0.4$ Hz, 1H), 7.86 (d, $J = 8.7$ Hz, 1H), 7.81 (dd, $J = 7.7, 0.2$ Hz, 1H), 7.78 (dd, $J = 7.7, 0.4$ Hz, 1H), 7.72 (tt, $J = 7.1, 1.5$ Hz, 1H), 7.58-7.50 (m, 8H), 7.16 (dd, $J = 7.5, 1.0$ Hz, 1H), 7.12 (dd, $J = 7.5, 1.0$ Hz, 1H), 7.09 (d, $J = 1.1$ Hz, 1H), 6.95-6.90 (m, 3H), 6.47 (dt, $J = 7.9, 0.9$ Hz, 1H), 6.40 (d, $J = 7.5$ Hz, 1H), 3.67 (s, 3H), 1.20 (s, 9H), 1.15 (s, 9H).

¹³C NMR (125 MHz, CD₂Cl₂) 190.0, 178.2 (2C), 174.9, 174.8, 163.3, 163.0, 159.5, 159.2, 152.5, 152.3, 149.4, 149.1, 145.8, 141.2, 139.6, 135.9, 135.1, 134.6, 134.3, 132.5, 131.7, 131.4, 131.3, 130.0, 129.6, 126.8, 126.5, 125.3, 124.8, 124.7, 124.5, 123.2, 123.1, 115.6, 115.4, 38.7, 35.2 (2C), 31.5, 31.4.

6. Single Crystal X-Ray Diffraction Studies

Crystals of **3s** and complex **I** were obtained by slow diffusion from a solution of the compounds in CH₂Cl₂ layered with *n*-hexane at room temperature for several days.

Crystal data and details of the structure determination are presented in Table S1. X-ray data were collected with a Bruker 3 circuit D8 Quest diffractometer with MoKa radiation (microfocus tube with multilayer optics) and Photon 100 CMOS detector at 115 K. Scaling and absorption correction was performed by using the SADABS⁵ software package of Bruker. Structures were solved using direct methods in SHELXT⁶ and refined using the full matrix least squares procedure in SHELXL-2014⁷. The hydrogen atoms were placed in calculated positions and refined as riding on their respective C atom, and Uiso(H) was set at 1.2 Ueq(Csp²) and 1.5 Ueq(Csp³). Disorder of PF₆ ions, solvent molecules or phenyl and *tert*-butyl groups was refined using restraints for both the geometry and the anisotropic displacement factors.




Figure S23. Crystal structure of **3s**. ORTEP drawing with 50 % probability thermal ellipsoids.




Figure S24. One of the two independent ions of complex **I** in the asymmetric unit. The hexafluorophosphate counteranion and the solvent molecules (hexane and DCM) are omitted for clarity. No disorder shown. ORTEP drawing with 50 % probability thermal ellipsoids.


Table S1. Crystal data and details of the structure determination.

| | 3s | complex I |
|---|--|---|
| Empiric formula | C ₂₅ H ₂₄ Cl N ₃ O | C _{48.4} H _{49.6} Cl ₂ F ₆ N ₄ O P Rh S ₂ |
| Formula weight | 417.92 | 1086.22 |
| Crystal system, space group | Orthorhombic, P2 ₁ 2 ₁ 2 ₁ | Triclinic, P-1 |
| <i>a</i> , <i>b</i> , <i>c</i> (Å) | 10.3206(4), 11.6585(5), 18.3971(8) | 17.1583(11), 17.7095(11), 18.8292(12) |
| α , β , γ (°) | 90, 90, 90 | 66.918(2), 69.054(2), 76.796(2) |
| <i>V</i> (Å ³) | 2213.59(16) | 4889.7(5) |
| <i>Z</i> | 4 | 4 |
| μ (mm ⁻¹) | 0.194 | 0.640 |
| Crystal size (mm) | 0.43 x 0.09 x 0.04 | 0.37 x 0.37 x 0.03 |
| <i>T</i> _{min} , <i>T</i> _{max} | 0.92, 0.99 | 0.98, 0.86 |
| No. of measured, independent and observed [<i>I</i> > 2 σ (<i>I</i>)] reflections | 12569, 4006, 3552 | 112817, 17855, 13904 |
| <i>R</i> _{int} | 0.0336 | 0.0533 |
| <i>R</i> [<i>F</i> ² > 2 σ (<i>F</i> ²)], <i>wR</i> (<i>F</i> ²), <i>S</i> | 0.0352, 0.0736, 1.060 | 0.0565, 0.1437, 1.039 |
| No. of used reflections | 4006 | 17855 |
| No. of parameters | 277 | 1548 |
| No. of restraints | 0 | 582 |
| $\Delta\rho_{\max}$, $\Delta\rho_{\min}$ (e Å ⁻³) | 0.148, -0.212 | 1.691, -0.833 |
| Absolute structure parameter | 0.08(3) | - |
| CCDC | 1480694 | 1480695 |


7. References


- 1) L. Ruiz Espelt, I. S. McPherson, E. M. Wiensch and T. P. Yoon, *J. Am. Chem. Soc.*, 2015, **137**, 2452-2455.
- 2) C. Wang, Y. Zheng, H. Huo, P. Röse, L. Zhang, K. Harms, G. Hilt and E. Meggers, *Chem. Eur. J.*, 2015, **21**, 7355-7359.
- 3) A. Sunderkötter, S. Lorenzen, R. Tacke and P. Kraft, *Chem. Eur. J.*, 2010, **16**, 7404-7421.
- 4) Y. Miyake, K. Nakajima and Y. Nishibayashi, *J. Am. Chem. Soc.*, 2012, **134**, 3338-3341.
- 5) *SADABS. Bruker AXS area detector scaling and absorption correction*, Bruker AXS Inc., Madison, Wisconsin, USA, 2014.
- 6) G. M. Sheldrick, *Acta Cryst. A*, 2008, **64**, 112-122.
- 7) G. M. Sheldrick, *SHELXT*, Universität Göttingen, Göttingen, Germany, 2014.

8. NMR Spectra





^1H NMR, CDCl_3 , 300MHz







¹³C NMR, CDCl₃, 75MHz







¹H NMR, CDCl₃, 300MHz







^{13}C NMR, CDCl_3 , 75MHz







^1H NMR, CDCl_3 , 300MHz










^1H NMR, CDCl_3 , 300MHz







^{13}C NMR, CDCl_3 , 75MHz







^1H NMR, CDCl_3 , 300MHz










¹H NMR, CDCl₃, 300MHz







^{13}C NMR, CDCl_3 , 75MHz







^1H NMR, CDCl_3 , 300MHz







^{13}C NMR, CDCl_3 , 75MHz







¹H NMR, CDCl₃, 300MHz







^{13}C NMR, CDCl_3 , 300MHz







^1H NMR, CDCl_3 , 300MHz







^{13}C NMR, CDCl_3 , 300MHz







^1H NMR, CDCl_3 , 300MHz







¹³C NMR, CDCl₃, 300MHz








¹H NMR, CDCl₃, 300MHz









^{13}C NMR, CDCl_3 , 300MHz





























¹H NMR, CDCl₃, 300MHz









¹H NMR, CDCl₃, 300MHz


















^{13}C NMR, CDCl_3 , 75MHz







$^1\text{H NMR}$, CD_2Cl_2 , 300MHz







^{13}C NMR, CD_2Cl_2 , 75MHz










^{13}C NMR, CDCl_3 , 75MHz







$^1\text{H NMR}$, CD_2Cl_2 , 500MHz










^1H NMR, CD_2Cl_2 , 500MHz










$^1\text{H NMR}$, CD_2Cl_2 , 500MHz







^{13}C NMR, CDCl_3 , 125MHz







^1H NMR, CD_2Cl_2 , 500MHz







^{13}C NMR, CD_2Cl_2 , 125MHz







$^1\text{H NMR}$, CD_2Cl_2 , 500MHz











$^1\text{H NMR}$, CDCl_3 , 300MHz















$^1\text{H NMR}$, CD_2Cl_2 , 500MHz










$^1\text{H NMR}$, CD_2Cl_2 , 500MHz







^{13}C NMR, CDCl_3 , 125MHz







$^1\text{H NMR}$, CDCl_3 , 500MHz











^1H NMR, CD_2Cl_2 , 500MHz















^1H NMR, CD_2Cl_2 , 500MHz










$^1\text{H NMR}$, CDCl_3 , 300MHz









¹H NMR, CDCl₃, 300MHz







$^1\text{H NMR}$, CD_2Cl_2 , 500MHz

